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ABSTRACT - Bacteroides fragilis Co-infection 
Polysaccharide A (PSA), a highly immunogenic capsular component of non-
toxigenic Bacteroides fragilis NCTC 9343 (NTBF), has been shown to promote host 
mucosal immune system development and to suppress inflammation in the gut. In stark 
contrast, enterotoxigenic Bacteroides fragilis (ETBF) induces IL-17 and is highly 
associated with inflammatory bowel disease and colorectal cancer, rapidly inducing acute 
colitis and tumorigenesis in murine hosts. The interactions of these distinct B. fragilis 
molecular subtypes were studied to determine the impact of NTBF on ETBF disease. In 
specific pathogen free (SPF) C57BL/6 WT and MinApc716+/- mice, we show that sequential 
treatment (NTBF then ETBF three days later) blunted colitis and decreased tumor 
development. Mice receiving simultaneous NTBF and ETBF treatment exhibited severe 
colitis and pronounced tumor formation. Abrogated disease severity in sequentially 
treated mice was attributed to NTBF strain dominance and decreased IL-17, but ETBF 
colonization prior to or simultaneous with NTBF mitigates the anti-inflammatory effect 
of NTBF. Surprisingly, NTBF-mediated protection was independent of polysaccharide A 
(PSA), as sequentially infected mice receiving ΔPSA NTBF exhibited similar levels of 
protection. Further, SPF WT and Min mice mono-associated with PSA-competent or 
PSA-deficient NTBF exhibit similar T cell-derived regulation, IL-17, and IFNγ 
responses. Daily NTBF probiotic treatment of mice stably colonized with ETBF failed to 
disrupt both ETBF strain dominance and niche occupation. Our findings demonstrate that 
NTBF may offer protection against ETBF disease but only under certain conditions. 
Disease outcomes are independent of PSA.  
	 iii	
Significance: In a murine model, NTBF mediated protection against ETBF colitis and 
tumorigenesis solely through competitive niche exclusion and not PSA expression. 
Colonization with Bacteroides fragilis, that is not infrequently ETBF, is common in the 
general population. Our results suggest that the probiotic capacity of NTBF to limit 
inflammatory disease in humans may be limited by prior colon mucosal ETBF 

















ABSTRACT - IL-22 in enterotoxigenic Bacteroides fragilis disease 
With purported roles in epithelial cell innate immunity and repair, the host-
protective immune signaling molecule, interleukin-22 (IL-22), may have a paradoxical 
effect on the development of colonic dysplasia. As of yet, the role of IL-22 in 
enterotoxigenic Bacteroides fragilis (ETBF)-mediated disease is unknown. In C57BL/6 
mice colonized with the human symbiote, ETBF, we show that an absence of IL-22 (IL-
22-/-) promotes increased epithelial cell shedding, intestinal permeability, and IL-17A and 
IL-11 pro-inflammatory signatures. Notably, ETBF-colonized MinApc716+/- IL-22-/- mice 
exhibited increases in tumor burden compared with parental controls. Furthermore, IL-22 
deficiency in ETBF-infected Min mice resulted in a further expansion of MHC class II 
low (ClassIIlow) macrophages of the myeloid lineage. Herein, we describe a role for IL-22 
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CHAPTER 1 - Introduction 
 
The Human Microbiota 
Current estimates for the ratio of bacterial cells to human cells is approximately 
1.3 to 1, 39 trillion bacterial cells to 30 trillion human cells 1 . Although this ratio is 
somewhat less impressive than the 10 to 1 ratio the scientific literature had assigned in 
the past, it is still undeniable that the mutualistic relationships that have evolved between 
humans and the microbiota influence every aspect of our physiology. From odor to 
nutrition to our health status to a significant driver of disease, we are becoming 
increasingly aware of the microbiome’s impact. Humans shed ~106, >0.5 µm diameter 
biological particles per hour that are likely to contain numerous bacteria2,3. Sampling 
airborne bacteria from air filters in a controlled environment, Meadow and colleagues 
recently showed that humans emit individualized microbial clouds and that individuals 
could also be identified by their specific microbial emissions 4 . Even the operational 
taxonomic units (OTUs) associated with the common vaginal microbes, Lactobacillus 
crispatus and Gardnerella vaginalus, were detected in the air surrounding the two female 
subjects, indicating the non-discreet nature of the personal microbial cloud leading to 
sex-relevant distinctions 4 . In turn, it is fascinating to consider the effects that our own 
microbiomes are having on the world around us, from our daily personal interactions to 
what signatures are left on what is termed the ‘built environment microbiome’, the 




Role of Host Genetics in Defining the Gut Microbiome 
Although there are many contributing factors, host genetics are likely at the crux 
of gut microbiome determination. For instance, a study comparing diverse mammalian 
fecal bacterial 16S ribosomal RNA profiles (from 13 taxonomic orders, including 60 
species housed in 2 separate zoos or in the wild) found that gut microbiomes retained 
similarity among animals that were related by phylogeny5. Even in 16 sampled humans 
spanning three continents and ages (27-94 years old), their gut microbiome profiles were 
more similar to each other than to other mammals5. Thus, in spite of differing dietary 
patterns and environmental exposures, host genetics may exert the largest influence on 
the microbiome. Consistently, studies of human twins show significantly more similarity 
in the gut microbiome compositions of monozygotic twins compared with dizygotic 
twins6–8.  
Even though fluctuations in the microbiome commonly occur, for instance, 
throughout the day as dictated by circadian rhythm and feeding patterns9, the long-term 
maintenance of microbial species appears to remain relatively stable over time within 
individuals10. Faith et al. showed that ~60% of total gut microbial strains were 
consistently detected in study subjects sampled over the course of 5 years with inferences 
made from a power law suggesting that harbored strains are likely maintained for decades 
or more10. Furthermore, another research study looked at the colonization of 
differentially-sourced microbes (e.g. zebrafish gut, termite hindgut, soil, and human 
feces) in germ free (GF) mice. It was found that the heterologous microbes could 
establish in GF hosts, yet co-housing of these mixed-microbiota mice with 
conventionally-colonized mice led to dominance by native mouse microbes and almost 
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an entire exclusion of the heterologous microbes11. This suggested an innate 
predisposition for host-specific species.  
Host-defined mechanisms and molecules also act to influence gut composition, 
for instance through antimicrobial peptide (AMP), immunoglobulin A (IgA), and 
microRNA secretion. For instance, 17 sampled human commensals, representative of the 
dominant bacterial phyla of the gut, exhibited broad resistance to numerous 
inflammation-associated AMPs, while common enteropathogens did not12. AMPs, 
typically small (12 to 50 amino acids), cationic, amphiphilic or hydrophobic, are 
generally thought to mediate cell damage by electrostatic binding to its target cell and 
induction of cell membrane permeability and depolarization13,14. One prominent human 
commensal, Bacteroides thetaiotaomicron (B. theta), has evolved to escape inflammation 
AMP damage through cleavage of the 4’ negatively-charged phosphate group of the 
lipopolysaccharide (LPS) lipid A anchor found in its outer membrane. Encoded by the 
lpxF gene, this cleavage neutralizes the bacterial negative charge, preventing AMP 
binding to the membrane12. lpxF mutant B. theta was rapidly outcompeted by wild type 
(WT) B. theta during experimental colitis in mice12. Suggestive of its mechanistic utility 
in humans, all sequenced human Bacteroidetes were found to contain LpxF orthologues, 
and all characterized lipid A LPS structures of this phylum were found to be under-
phosphorylated12.  
Another form of host control occurs through the production of antibodies, with 
IgA being the most abundant Ig isotype found at the mucosal surface. In a study looking 
at mice that were deficient in activation-induced cytidine deaminase (AID), the driver of 
antibody hypermutation, the burden of intestinal segmented filamentous bacteria (SFB) 
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was strikingly enriched. It appeared that lack of functional IgA contributed to aberrant 
immune responses and increased bacterial burden15. SFB dysbiosis and immune 
activation in AID-deficient mice were both rescued by parabiosis16 (a surgical union 
allowing for shared blood circulation) with WT mice. This IgA restoration prevented 
SFB mucosal localization15.  
Host microbiome regulation can also be perpetuated through production of 
circulating microRNAs (miRNAs), small (18 to 23 nucleotides), non-coding RNAs with 
complementary binding to mRNA transcripts typically resulting in their silencing. Liu 
and colleagues recently identified an abundance of fecal miRNAs in sampled human and 
murine feces and described their potential ability to enter and directly alter gene 
expression of bacteria. Specific miRNAs appeared capable of entering Escherichia coli 
and Fusobacterium nucleatum, co-localizing with bacterial nucleic acids, and leading to a 
promotion of bacterial growth17. Additionally, in mice with intestinal epithelial cell (IEC) 
specific loss of Dicer (Dicer1DIEC), the crucial miRNA processing enzyme, their gut 
microbiomes were distinct from Dicer-competent (Dicer1fl/fl) littermates, and they were 
also more susceptible to dextran sulfate sodium (DSS)-induced colitis. Microbiome 
similarity and disease protection, presumably through the shaping of specific symbiotic 
bacteria that regulate intestinal barrier function, were restored after WT miRNA fecal 
transfer to Dicer1DIEC mice17. Altogether, these findings provide robust examples of host-





Establishment of Microbiome Symbiosis 
Throughout development, humans and other mammals establish a complex 
symbiosis with microorganisms from numerous environmental exposures. This begins at 
birth, during exposure to the maternal vaginal microbiota18 in the birth canal and 
continues throughout breastfeeding, where the infant gut becomes exposed to the milk-
associated microbiota19 . Infants are exposed to maternal antibodies that protect against 
harmful organisms20, and the digestion of milk oligosaccharides also aids the selection of 
particular bacterial genera21, such as Bifidobacterium and Bacteroides22. The transition to 
solid foods coincides with a shift towards a more adult-like microbiota (typically by the 
age of 3) with increased diversity and increased abundance of anaerobic Firmicutes23. 
Old age is also associated with microbial shifts accompanied by diminished diversity24 , 
increased Enterobacteriaceae, and decreased Bifidobacteria25.  Indicative of the vast co-
evolution that has occurred between the human host and microbiota, the adult intestinal 
ecosystem is distinct from other evaluated microbial communities26 and even contains 
many species not found anywhere else in nature. 
Constantly bombarded with a milieu of microorganisms and other foreign 
products through food consumption, the mucosal immune system must establish a form 
of equilibrium. On the one hand, it must readily detect and defend against pathogens, e.g. 
enterohemorrhagic E. coli and Vibrio cholerae, yet robust immune responses to every 
microbe or product encountered in the gut lumen would lead to inflammatory reactions 
detrimental to the host. The research also shows that exposure to commensal microbes is 
essential for proper immune system maturation, thus the host requires a controlled 
immune response to these harmless and likely beneficial organisms27. This tolerant co-
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existence allows us to reap the benefits of a healthy microbiota that aids in nutrient and 
drug metabolism, intestinal barrier function, and competitive exclusion of pathogenic 
organisms.  
The analysis of fecal 16S rRNA sequences along with metagenomic sequencing 
data shows that Firmicutes, Bacteriodetes, and Actinobacteria phyla are dominant in 
healthy people, while Proteobacteria and Verrucomicrobia are present to a lesser extent28. 
Low abundance of Proteobacteria accompanied with high abundance of Bacteroides, 
Prevotella, and Ruminococcus genera are also suggestive of a healthy state29. 
Furthermore, there are commonly detected ‘phylotypes’, which also include unculturable 
microbial species, that colonize healthy individuals. A recent study analyzing the feces of 
17 healthy adults yielded 66 abundant phylotypes, common to and detected in greater 
than half of study subjects30. Comparison of these findings with other publicly available 
data sets of the fecal microbiome from healthy humans show strong overlap, with 52 of 
the phylotypes (78.8%) being detected in three out of four of these libraries. In spite of 
individual subject variability, these data strongly suggest the existence of a phylogenetic 
core of healthy human intestinal microbes.  
Although the fecal microbiota of healthy adults appears stable over time, gut 
composition fluctuations can be induced by dietary changes in the short-term and long-
term. For instance, a diet high in non-digestible carbohydrates induced microbial shifts 
high in Bifidobacterium within 2 to 3 weeks28. Additionally, Wu et al. recently showed 
that a long-term high fiber diet is associated with Prevotella spp., while a high protein 
diet is associated with Bacteroides spp. in a study population of 96 adults31. 
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Dysbiosis and Disease Implications 
As previously mentioned, the intestinal microbiota has been shown to follow a 
diurnal rhythm, with oscillations occurring in the abundant Bacteroidales, Clostridiales, 
and Lactobacillalus taxonomic orders. However, in mice lacking a functional circadian 
clock (Per1/2-/-), these microbial oscillations were ablated9. Thaiss and colleagues found 
that internal clock-directed feeding patterns drove these microbial fluctuations. As 
nocturnal animals, WT mice fed primarily during the dark phase, yet Per1/2-/- mice fed 
constantly throughout the day. When Per1/2-/- mice were given controlled access to food 
only during the dark phase, proper microbial rhythms were restored. The initiation of jet 
lag in mice (an 8-hour time shift every 3 days) and observations in jet-lagged (an 8- to 
10-hour time shift) healthy human subjects yielded disrupted intestinal microbial rhythms 
and microbial dysbiosis9.  
Fascinatingly, the fecal transfer from jet-lagged mice and humans to GF mouse 
recipients initiated metabolic disease, evident by increased weight gain and glucose 
intolerance compared with controls remaining on a normal circadian rhythm9. In this era 
of industrialization, disruptions to the human circadian clock have arisen from increased 
chronic shift work and the increased convenience of travel across different time zones. 
Such circadian misalignment has become associated with the development of numerous 
diseases, including obesity, cancer, diabetes, cardiovascular disease, and susceptibility to 
infection32–36. The findings of the described study provide evidence of a man-made 
synchronized circadian and microbial dysbiosis that may significantly impact human 
health. 
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In the context of intestinal disease, strong evidence exists for the role of the 
microbiota in both inflammatory bowel disease (IBD) and colorectal cancer (CRC). IBD 
is defined as a chronic inflammation of the gastrointestinal (GI) tract with periods of 
chronic remission and relapse, typically organized into Crohn’s disease (CD) or 
ulcerative colitis (UC). Although the etiology of IBD is not fully understood, in 
genetically predisposed individuals, inflammation is attributed to aberrant mucosal 
immune responses to commensal gut bacteria37. Further meta-analysis showed improved 
remission rates in active CD and UC patients treated with antibiotics over the placebo-
treated group38. 
Many IBD loci that have been discovered (e.g. NOD2, STAT3, and ATG16L1) are 
associated with innate immunity and defense against enteric bacteria39,40. Such genetic 
variants can contribute to the overgrowth of specific microbial species, likely playing a 
role in inducing an overzealous immune response41. For example, mutations in 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) are one of the 
strongest risk factors for IBD42–44. NOD2 senses muramyl dipeptide, a bacterial cell wall 
component, intracellularly, inducing NF-kB and MAPK signaling. This initiates 
production of AMPs, cytokines, and T cell co-stimulatory molecules leading to their 
activation45,46. Indeed, the absence of functional NOD2 in mice disrupts immune 
homeostasis, promoting aberrant mucosal immune responses to commensals and also 
increasing the bacterial load47,48. NOD2-deficient mice also displayed a predisposition to 
developing colitis induced by DSS and azoxymethane (AOM)49. Genetic alterations in 
known IBD loci (e.g. NOD2, T-bet, Rag2, IL10, and Tlr5) have also been shown to 
promote the development of a dysbiotic microbiome that, when transferred to healthy test 
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animals, initiates disease50,51. In the example of NOD2, administration of feces from 
NOD2-deficient mice to GF WT mice (NOD2-/-àGF-NOD2+/+) transferred the increased 
risk of colitis to recipients. Fecal transfer (NOD2-/-àGF-NOD2+/+; NOD2-/-àGF- NOD2-
/-) was accompanied by microbiome composition shifts in Bacteroides (increased), 
Butyrivibrio (decreased), and Lachnobacterium (decreased) compared with recipients of 
specific pathogen free (SPF) WT feces49. This microbiota transfer appeared to sensitize 
the colons of WT mice to chemically-induced colitis through alterations in epithelial cell 
barrier function; for instance, enhanced claudin-5 (Cldn5) expression, a protein 
component of the tight junction strands, was observed in the colons of WT mice that had 
been co-housed with NOD-2 deficient or RIP2-deficient mice. Notably, the transfer of 
WT feces to NOD2-deficient animals (NOD2+/+àGF-NOD2-/-) rescued them from 
disease development49.  
Parallel to the results of mouse models, microbiota shifts are also observed in 
humans afflicted with intestinal inflammatory conditions. For instance, an overall 
decrease in microbial diversity is observed in the microbiomes of IBD and CRC patients 
in comparison with healthy controls52,53. In IBD, decreased burden and diversity within 
the Firmicutes and Bacteroidetes phyla are noted, whereas increased Enterobacteriaceae 
(Proteobacteria phyla), specifically of adherent E. coli, are observed52,54. Of interest, a 
474-person microbiome genome-wide association study (mGWAS) yielded that 
individuals with variants in the risk allele, NOD2, had specific enrichment in 
Enterobacteriaceae55. In addition, stool samples from CRC patients demonstrate an 
increase in the Bacteroides and Prevotella genera and associations with the Actinomyces, 
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Atopobium, Fusobacterium, and Haemophilus genera compared to colonoscopy 
controls56,57. 
In trying to elucidate microbial contributions to CRC development, three 
hypotheses exist: potential influences from 1) single microbes, 2) the microbial 
community, or 3) the interactions of single microbes with the microbial community 
directing a pathogenic microbiota58. In this composition, the contributions of single 
microbes to CRC development will be investigated. Through human association studies 
and animal models, several symbiotic microbes, including enterotoxigenic Bacteroides 
fragilis, F. nucleatum, E. coli, Streptococcus gallolyticus, and the Enterococcus spp., 
have a purported role in colorectal cancer59. These microbes may initiate or promote the 
progression of cancer indirectly or directly through the recruitment of inflammatory cells 
producing copious amounts of reactive oxygen species, or through bacterial-derived 
factors or toxins that can be highly damaging to DNA, alter cellular proliferation, and 
induce apoptosis60. Altogether, such findings suggest that targeted intestinal microbial 
manipulation of the host could lead to improvements in disease prevention and/or disease 
outcome for patients at risk or are undergoing treatment for CRC and IBD.  
 
Enterotoxigenic Bacteroides fragilis 
Bacteroides fragilis is a Gram-negative, obligate anaerobic bacterium known to 
typically reside in the lower gastrointestinal tracts of mammals and comprising only < 1 
to 2% of the cultured fecal flora61,62. B. fragilis is a common commensal of humans; 
Zitomersky et al. found that 87% of adults were fecally colonized with B. fragilis63 . 
Enterotoxigenic B. fragilis (ETBF) was originally discovered during study of the etiology 
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of newborn lamb diarrheal disease on ranches in the Rocky Mountain Region of the 
United States64. B. fragilis was isolated from the feces of young lambs with acute 
diarrhea, and enterotoxin activity was subsequently confirmed through the lamb intestinal 
loop (LIL) test. The LIL test utilized the creation of multiple isolated segments of the 
small intestine, created by surgical ligation, and inoculation of various test diarrheic 
feces, test bacteria, or controls into individual segments; the secretory phenotype of test 
samples was then measured by visually scoring the fluid accumulation within segments64. 
Inoculation with pure cultures of isolated fecal ETBF caused acute enteric disease in a 
subset of newborn lambs, and further ETBF-associated piglet, calf, and foal diarrheal 
illness would later be reported. A secreted heat-labile protein toxin was identified as the 
initiator of intestinal secretion.  
In an uncontrolled study in 1987, ETBF was first isolated in diarrheic humans 
from Montana (10 subjects) and infants (34 subjects, 2-14 months old) from the Navajo 
Area Indian Reservation in Tuba City, Arizona65. ETBF isolates were detected in 8 of 44 
subjects (2 adults and 6 children <5 years old)65. Three other uncontrolled clinical reports 
from Warsaw, Poland, provided further evidence of ETBF isolation from diarrheal 
patients: 1994 study in children (n=120; 16.7% of stools were B. fragilis positive; 2 
children were ETBF positive)66, 1999 study (n=50; 17/50 (34%) of stools were B. fragilis 
positive; 4/17 (23%) were ETBF positive)67, 2003 study in children and adults (n=332; 
50/332 (15%) of stools were B. fragilis positive; 9/50 (18%) were ETBF positive)68. In 
1992, the first study including control subjects was conducted in pediatric outpatient 
clinics of the Apache Indian Reservation in Whitewater, Arizona; the study found ETBF 
isolates associated with diarrhea in children 1 to 5 years old but not in children < 1 year 
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old (n=275; overall, 12% diarrheic patients and 6% control subjects were ETBF positive), 
with strains isolated within families seemingly genetically related69. Although variable in 
nature, in total, the results of 12 of 17 controlled studies combining research in children 
and adults, showed associations with ETBF and diarrheal disease62. Collectively, the data 
suggest that ETBF is an etiologic agent of diarrheal disease in both children and adults 
with global distribution. ETBF illness in humans is typically characterized by an acute, 
self-limiting watery diarrhea with persistent diarrhea noted only in a small subset of 
patients. Even still, asymptomatic colonization with ETBF is common with earlier studies 
collectively reporting 2% to 30% detection62, and a recent study reporting fecal detection 
in 40% of healthy individuals (6 out of 15 subjects in Boston, MA)63. 
Bacterial members of the enterotoxigenic B. fragilis subgroup were discovered to 
carry and secrete the B. fragilis toxin, or BFT, genomically encoded on a ~6 kb 
pathogenicity island70. Seminal work in human carcinoma cell lines showed that BFT, a 
20 kDa zinc metalloprotease, severely alters the colon epithelium cell-to-cell adherens 
junctions through the cleavage of E-cadherin, disrupting barrier function and stimulating 
the Wnt signaling pathway to induce proto-oncogenes and other cell proliferative genes, 
such as c-Myc71,72. Later, ETBF was observed to cause marked colonic inflammation and 
tumor development in mice73–75. Moreover, a milieu of pro-inflammatory cytokines is 
produced, most notably IL-17A, required for ETBF pathogenesis75. Recent insights by 
our group have also been made into the complex interplay of IL-17, NF-κB, and STAT-3 
signaling in the ETBF model. IL-17A directly influences colon epithelial cell (CEC) NF-
κB signaling, inducing an NF-κB-dependent CXCL1 chemokine gradient leading to a 
critical homing of pro-tumoral myeloid cells to the distal colon region, the distinct site of 
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ETBF-induced tumors in genetically predisposed Apc+/- or Min mice (Chung et al. – 
under review). Furthermore, STAT-3 activation in CECs is also required for colon 
tumorigenesis, while IL-17A-producing cells (CD4+ and γδ T cells) and infiltrating 
myeloid cells drive persistent colonic inflammation76,77.  
 
Non-enterotoxigenic Bacteroides fragilis 
Another molecular subset of B. fragilis is designated as non-enterotoxigenic B. 
fragilis (NTBF), which do not encode the pathogenicity island (BfPAI) containing the bft 
gene. Beyond its association with diarrheal disease, historically, B. fragilis has been the 
most commonly isolated obligate anaerobe in human infections including intra-
abdominal abscesses and bacteremia78,79. Intraperitoneal (i.p.) administration of 
encapsulated B. fragilis or its capsular polysaccharide complex (CPC) along with sterile 
cecal contents to rodents induced abscess formation80. Pathogenicity was later attributed 
to a unique, zwitterionically charged component of the CPC (a repeating tetrasaccharide 
unit with a balanced positively charged amino group and negatively charged carboxyl 
group), capable of inducing T cell activation and prompting abscess formation81. 
Chemical modifications to either charge of the polysaccharide markedly reduced its 
ability to induce abscesses, whereas an un-related Salmonella typhi polysaccharide 
capsule (Vi antigen), containing one negative charge, could be modified to an abscess-
inducing form by introducing an additional positive charge82. In contrast, when B. fragilis 
is allowed to remain in its primary ecological niche, the mammalian colon, its CPC 
initiates a non-harmful, host-protective regulatory T cell response, a phenomenon that 
will be later investigated in this work. Interestingly, rats exposed subcutaneously to the 
	 14	
high molecular weight polysaccharide A (PSA) component of the CPC prior to i.p. 
bacterial administration were protected from abscess formation in a T cell-dependent 
manner83.  
In lieu of the fact that bacterial polysaccharides have been strictly viewed as T-
cell independent antigens, these findings were incredibly novel. Passive transfer of 
antibodies from CPC-immunized rats to un-immunized rats conferred protection against 
B. fragilis bacteremia but not abscess formation, while adoptive transfer of splenocytes 
from CPC-immunized rats did prevent abscesses84. Crucial in vitro experiments also 
showed that purified PSA could only induce CD4+ T cell proliferation in the presence of 
antigen presenting cells (APCs)85. Further computer modeling studies on the closely 
related molecule, PSA2 from B. fragilis clinical isolate 638R, showed a theoretical 
charged-based binding of PSA2 into the alpha-helical peptide groove boundaries of MHC 
class II molecules86. Confocal microscopy experiments further strengthened these data by 
showing the visualization of PSA at the immunological synapse between APCs (MHC 
class II) and T cells (αβ TCR)87. These studies and numerous others have continued to 
provide strong evidence for the non-traditional processing and presentation of 
polysaccharide A (PSA), the recognized immunodominant component of the CPC, to 
CD4+ T cells leading to their activation. Since the exciting discovery of these distinctive 
CPC immunochemical properties, the biological function of these structures in gut health 
has continued to be researched.  
Although the B. fragilis CPC was initially thought to be comprised of only 2 high 
molecular weight molecules, the heavily studied polysaccharides A and B (PSA and 
PSB), genomic analysis later revealed that B. fragilis can produce at least 8 distinct 
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capsular polysaccharides (denoted A through H). This number is more than described for 
any bacteria outside of the Bacteroidales order; thus 133 kb of the B. fragilis genome is 
devoted to capsular polysaccharide synthesis88. Within a bacterial population in vitro, 
only a portion of the culture will be expressing any one polysaccharide with even dual or 
no expression observed when double-labeling experiments were performed. Analysis of 
sorted bacterial PSA-on and PSA-off populations after re-culturing yielded a mix of on 
and off populations within each subset, showing that polysaccharide phase variation 
exhibits a reversible on-off phenotype88. Excluding PSC, phase variation was shown to be 
regulated first through a novel system of invertible promoter regions located upstream of 
each set of polysaccharide synthesis loci, upxY (where x represents locus a – h, excluding 
c), rendering the promoter in the correct or incorrect orientation needed for 
transcription88. The second level of regulation occurs through UpxZ which acts to inhibit 
UpxY, a transcriptional anti-termination factor; UpxZ regulation allows for heterologous 
loci inhibition, ensuring that B. fragilis only synthesizes one polysaccharide at a time89.  
Thus, the previous observation of dual B. fragilis PS expression by labeling is 
likely a result of a phenotypic lag. And although expression of at least one polysaccharide 
is required for competitive colonization of the gut, the utility of multiple phase-variable 
polysaccharides is still being elucidated90. Longitudinal analysis of 15 healthy subjects 
over the course of a year revealed that IgA responses were not mounted to several 
Bacteriodales strains detected at a high burden in the host. In spite of the possible 
prospect that phase variation evolved as an IgA-dependent mechanism to evade the host 
immune response, similar, for example, to Giardia lamblia, there were no correlations 
observed between IgA responses and the elimination of strains or notable alterations in 
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the orientation of their respective invertible polysaccharide promoters63. Thus, it appears 
that the IgA response does not shape Bacteriodales composition in the adult gut but may 
have a role in compartmentalizing or keeping specific microbes at bay from the mucosal 
epithelium. 
 
Bacteroides fragilis bacteriocins 
The bacterial equivalents of antimicrobial peptides are typically referred to as 
bacteriocins. These antimicrobials or bacteriocins were first discovered about a century 
ago in E. coli, when it was observed that E. coli V could inhibit growth of E. coli S91. 
Initially designated as colicins, these bacterial products were later identified as proteins 
having activity on bacterial cells dependent on the presence or absence of specific 
receptors92. Since then, bacteriocins have been discovered among all major lineages of 
Bacteria with the suggestion by Klaenhammer et al., that 99% of bacteria may produce at 
least one93. Bacteriocins are distinct from classical antibiotics in that they are ribosomally 
synthesized and have a narrow killing spectrum, typically acting on closely related 
species or within the same species; specificity is likely receptor-mediated14,94. These 
proteinaceous toxins come in a variety of sizes, targets, and modes of action, typically 
acting in the same fashion as eukaryotic AMPs, through membrane permeabilization and 
nucleic acid degradation or inhibition mechanisms14,95.  
Having been used as an epidemiological typing method, numerous clinical 
isolates of Bacteroides produce and are sensitive to bacteriocins96,97. For instance, in a 
study of B. fragilis clinical isolates from hospitals in Athens, Greece, 94% of isolates (30 
of 32) were discovered to inhibit at least one other B. fragilis strain, while one strain was 
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even discovered to inhibit 17 strains. Similarly, sensitivity to at least one other B. fragilis 
strain was found in 94% of isolates, while one strain was determined to be sensitive to 17 
test strains97. An inverse relationship appeared to exist between the number of 
bacteriocins produced and the number of bacteriocins to which they were sensitive. 
Although not heavily studied within the Bacteroides field, one bacteriocin characterized 
from a human fecal isolate (Bf-1) uniquely inhibited RNA synthesis as its mode of 
action98. In another early study, in the human colon, researchers found that bacteriocin-
susceptible Bacteroides co-existed in large numbers with bacteriocin-producers99. 
Seemingly counter to the hypothesis that bacteriocin production confers an advantage 
over non-producers, it is possible that bacteriocin production permits bacteria to persist at 
low levels or even gain access to a specialized microenvironment. It remains unclear 
what this array of natural antimicrobial responses means for human health, yet it seems 
that bacteriocins are contributing factors to gut microbial composition, stability, and 
dynamics.  
Their high potency, specificity, and fast-killing of targets, also make bacteriocins 
possible candidates for the treatment of bacterial infections. For instance, Casey et al.100 
and Walsh et al.101 demonstrated that administration of milk that had been supplemented 
with bacteriocin-producing strains of lactic acid bacteria (LAB), helped to ameliorate 
Salmonella-induced diarrhea in pigs. An additional study by Corr et al. showed that 
colonization of mice with Lactobacillus salivarius UCC118 protected from Listeria 
monocytogenes infection, an invasive foodborne pathogen; protection was mediated 
through the L. salivarius production of a class IIb bacteriocin, Abp118, shown to have 
direct action on the pathogenic Listeria strains102. Furthermore, peptide engineering may 
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create bacteriocins that can be delivered even more efficiently. For example, 
pheromonicin AgrD1 is a recombinant peptide comprised of the agrD1 Staphylococcus 
aureus pheromone gene fused to colicin Ia103. Fusion to AgrD1 allows for colicin Ia 
passage through the cell wall of S. aureus, a non-native target, promoting killing of 
methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) in 
vitro and in a MRSA mouse infection model103. 
 
Colorectal Cancer Burden  
In 2012, worldwide, there were an estimated 1.4 million new cases and 693,900 
deaths resulting from colorectal cancer with the highest incidence levels occurring in 
North America, Europe, New Zealand, and Australia104. In the United States, CRC is the 
second leading cause of cancer-related deaths and is the fourth most common malignant 
neoplasm when both sexes are combined105. Yet, CRC cases are emerging in locations 
previously considered to be low risk, including South America, Eastern Europe, and 
Eastern Asia104,106. This rise in global incidence is likely, in part, due to globalization and 
its far-reaching impacts on changes towards more westernized dietary patterns, lifestyle, 
obesity, and other CRC risk factors106,107.  
As an example, since African Americans are disproportionately affected by CRC 
in the U.S., O’Keefe and colleagues conducted a series of studies analyzing diet, specific 
biomarkers, and polyp detection in African Americans compared with rural South 
Africans108. At baseline, African Americans had a diet 2 to 3 times higher in animal 
protein and fat compared with rural South Africans who had a diet high in carbohydrates 
and fiber, typically resistant starches; polyp detection and mucosal proliferation, as 
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measured by marker Ki67, were also distinctly higher in African Americans108. 
Interestingly, when African Americans were switched to an African diet (low fat, high 
fiber) for two weeks, putative anti-carcinogenic properties such as saccharolytic 
fermentation and butyrate production increased, while potentially cancer-promoting 
features such as secondary bile acid synthesis, epithelial cell proliferation, and colonic 
mucosal inflammation diminished108. Conversely, Africans put on an American diet (high 
fat, low fiber) for two weeks showed a reversal in all outcomes. Microbiota changes were 
also observed: both Africans and African Americans on an African diet exhibited higher 
levels of microbial functional genes associated with butyrate production (bcoA) and end-
product hydrogen removal by methanogens (mcrA) and sulfate-reducing bacteria (dsrA); 
the crucial secondary bile acid synthesis gene, baiCD, was diminished in these groups.  
Similarly, a study of Japanese migrants to Hawaii and California showed that 
CRC rates swiftly reached levels typical of Caucasian populations, within one 
generation109. The authors showed that high CRC risk in Japanese migrants was likely 
dependent on dietary changes, specifically the high intake of red meat combined with a 
rapid N-acetyltransferase (NAT2) variant predominant within the Japanese population 
(90% in Japanese vs 45% in Caucasians) coupled with a rapid N-oxidation (CYP1A2) 
variant. A combination of rapid CYP1A2 and NAT2 phenotypes may lead to more 
efficient metabolic activation and binding, respectively, of potentially genotoxic 
heterocyclic aromatic amines (HAAs) that are present in meats cooked at high 
temperature, to host DNA109. This study suggests a convergence of shifting diet and 
genetic factors contributing to increased CRC risk in a specific population.  
Strikingly, by 2035, CRC incidence is expected to increase by 80%, projected to 
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cause 2.4 million cases and 1.3 million deaths106. Furthermore, IBD, characterized by 
chronic inflammation within the gastrointestinal tract, increases risk for development of 
CRC by 10-15%110 with the overall risk of CRC in IBD patients (both Crohn’s and 
ulcerative colitis) estimated as 1.7 times higher than the general population111. Most 
alarming, both CRC incidence and mortality in young adults (< 50 years old) has begun a 
distinct increase in the United States and elsewhere112–114. In spite of CRC age-specific 
risk having shown a steady decline in the first half of the 20th century (~1890 through 
1950), recent analysis shows that CRC risk in the 1990 birth cohort, individuals now in 
their early 20s and 30s, has begun to approximate the CRC risk last observed in the 1890 
birth cohort115. In other words, compared with individuals born in the year 1950, the 1890 
birth cohort exhibited a doubled risk for colon cancer and a tripled risk for rectal cancer; 
in the same way, young people of the 1990 birth cohort now exhibit a doubled risk for 
colon cancer and a striking quadrupled risk for rectal cancer115.  
It is unclear what factors may be driving this resurgence in young people, 
although this increased CRC incidence appears to parallel increased obesity rates (both 
duration and degree of obesity) observed in recent birth cohorts116. There is evidence 
suggesting that every 5-unit increase in body mass index is associated with a 13% to 18% 
increased CRC risk112,117–119. Other preliminary studies note that young-onset CRCs 
typically occur in the distal colon and rectum, displaying specific histological distinctions 
from older-onset CRCs: poorly differentiated, mucinous, and signet ring features120,121; 
these findings may suggest that molecular differences exist between younger- and older-
onset CRCs. Additionally, possibly due to lower screening rates and unrecognized 
symptoms in the population, younger-onset CRC is more likely detected at advanced 
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stages, e.g. stage III & IV., than older-onset CRC (respectively, in colon cancer: 63.4% 
vs 49.0%, p<0.01; respectively, in rectal cancer: 57.3% vs 46.2%, p<0.01)120.  
Furthermore, although the risk of dying from CRC has generally decreased in the 
overall population, it has begun to rise in those aged 20 to 54 years old: from 3.9 deaths 
per 100,000 in 2004, to 4.3 deaths per 100,000 in 2014122. These surprising early findings 
suggest that the burden of CRC is shifting towards the younger population, and further 
research will be necessary to determine the underlying causes of this increased disease 
risk and mortality. Collectively, it is clear that augmented, population-accessible 






CHAPTER 2 - Bacteroides fragilis Co-infection 
 
Background 
Probiotics, defined as living microorganisms that confer a health benefit to the 
host when administered in adequate amounts123, are proposed for both disease prevention 
and therapy. Clinical studies assessing the effectiveness of probiotics as supplemental 
treatments in IBD and CRC have shown promise. For instance, single bacterial species, 
such as E. coli Nissle 1917, or multispecies cocktails, such as VSL#3 (containing 
Streptococcus salivarius and multiple species of Lactobacilli and Bifidobacteria), aid in 
the prevention or recurrence of post-operative pouchitis and in the therapy of active 
ulcerative colitis124. In CRC, oral treatment with Lactobacillus casei Shirota resolved 
atypia of colon tumors in patients who underwent colon resection125. Perioperative 
treatment in CRC resection patients with combination probiotics led to reductions in 
serum zonulin (a marker of intestinal permeability), bacterial translocation, and 
septicemia, while Yang et al. further described reductions in both gut-related 
complications and recovery time to bowel function126–128. The human colon symbiote 
non-toxigenic Bacteroides fragilis (NTBF type strain NCTC 9343) has been proposed as 
a probiotic due to its anti-inflammatory actions including the initiation of regulatory T 
cell expansion and production of IL-10, a characteristic immunosuppressive cytokine129, 
as well as to limit pathogenic Th17 development130. These activities have been ascribed 
to expression of an NTBF-derived capsular component, polysaccharide A (PSA), also 
proposed as a potential probiotic molecule. 
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In contrast, another molecular subgroup of B. fragilis, enterotoxigenic 
Bacteroides fragilis (ETBF) that secretes the B. fragilis toxin, BFT, induces marked 
colonic inflammation and tumor development in mice73–75. BFT, a 20 kDa zinc 
metalloprotease, severely alters cell-to-cell adherens junctions in the colon epithelium 
through the cleavage of E-cadherin, disrupting barrier function and stimulating the Wnt 
signaling pathway to induce proto-oncogenes and other cell proliferative genes, such as 
c-Myc71,72. Moreover, a milieu of pro-inflammatory cytokines is produced, most notably 
IL-17A, required for ETBF pathogenesis75. It is an enticing prospect that probiotic 
organisms may have the potential to disrupt the cycle of ETBF pathogenic signaling, 
lessening the burden of disease.  
Humans are commonly colonized with B. fragilis, a bacterium with known 
proclivity for the colon mucosa. Thus, we tested the hypothesis that the 
immunoregulatory probiotic, NTBF, can protect against ETBF-mediated disease. We 
found when NTBF colonized at high levels in the colon, prior to ETBF treatment, the 
NTBF strain limited inflammation and tumor development in mice. However, this 
protective effect was independent of NTBF-encoded polysaccharide A or direct host 
immune system modulation, and rather, appeared to be solely mediated by competitive 
exclusion and mucosal NTBF strain dominance. Daily NTBF therapeutic treatment of 
mice stably infected with ETBF failed to diminish colitis or ETBF strain dominance. 
Together our results suggest that the capacity of NTBF to act as an anti-inflammatory 




Materials and Methods 
 
Bacterial Strains and Growth 
B. fragilis strains NCTC 9343 (NTBF) and 86-5443-2-2 (ETBF) were used for all 
experiments74,75,131. The PSA-deficient isogenic mutant, ΔPSA NTBF, was graciously 
provided by L. Comstock (Harvard University). All strains were clindamycin-resistant: 
ETBF strains (naturally) and NTBF strains (pFD340-transformed to confer resistance). 
Strains were grown anaerobically at 37oC with brain-heart infusion (37 g/L; BD Bacto) 
culture media or agar plates (1.5% BD Bacto Agar) supplemented with yeast extract (5 
g/L; BD Bacto), L-cysteine (50 mg/L; Sigma), hemin (0.5 mg/L; Sigma), and vitamin K 
(0.1 mg/L; Sigma). For all mouse experiments, glycerol stocks of NTBF and ETBF were 
streaked onto BHI clindamycin (10 µg/L; Research Products International) plates with 
pure, isolated colonies sub-cultured in BHI clindamycin media for ~24 hours. For mouse 
inoculums, bacterial pellets were washed twice and resuspended with 1X Dulbecco’s 
phosphate buffered saline (1X PBS free calcium chloride & magnesium chloride).  
For individual growth curves, strains were grown to mid-logarithmic phase 
simultaneously, diluted to an OD600 of 0.1 to a fresh pre-warmed, pre-reduced anaerobic 
culture tube (BHI clindamycin) and monitored every hour for 8 hours and at 24 hours. 
Bacterial turbidity was monitored by spectrophotometer (600 nm) and subcultures 
performed (48 hours incubation) to quantitate viable colony forming per unit volume 
(CFU/ml). For in vitro co-inoculation assays, NTBF and ETBF were grown to mid-
logarithmic phase and either introduced to a fresh culture tube (BHI clindamycin) at 
equal parts or at varying ratios (NTBF to ETBF: roughly 10:90, 50:50, 60:40, 90:10) and 
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cultured for up to 48 hours. At each sampling time point, subcultures were performed to 
allow random selection of ten colonies to test for colony identification (NTBF vs ETBF) 
using strain-specific PCRs (Supp. Table 1)132,133. Percentages of NTBF and ETBF 
positive colonies within the in vitro culture were then determined. All assays were run in 
triplicate. 
For agar diffusion assays, NTBF and ETBF strains were grown separately in BHI 
media (no antibiotics). After 48 hours, bacterial suspensions were centrifuged (13,000 
rpm, 5 minutes) and culture supernatants sterile filtered (0.22 µm). 500 µl of the indicator 
strain, NTBF, was mixed with 12 ml of BHI soft agar (0.7%); after drying, hole punches 
(6 mm) were created, sealed with 35 µl of soft agar, and inoculated with 100 µl of cell-
free supernatants. Plates were grown anaerobically overnight and observed for an 
inhibition zone. Treatments of supernatants consisted of trypsin (200 µg/ml, 2 hours, 
37oC), proteinase-K (100 µg/ml, 2 hours, 37oC), and heat inactivation (15 minutes, 
100oC). 
 
Mice and Infection Model 
Specific pathogen free (SPF) C57BL/6 WT mice and C57BL/6 MinApc716+/- mice 
(obtained from Dr. David Huso, Johns Hopkins University, Baltimore, MD) were used 
for all experiments. C57BL/6 WT mice were originally purchased from Jackson 
Laboratories and strictly maintained in house. MinApc716+/- heterozygosity was maintained 
with C57BL/6 WT female breeders. Mice at 3 to 4 weeks of age were placed on 
antibiotic water bottles (clindamycin 0.1 g/L and streptomycin 5 g/L) (Hospira and 
Amresco) for 5 to 7 days and discontinued. Mice were then gavaged with ~108 CFU of 
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NTBF and/or ETBF (100 µl total volume in 1X PBS) either singly, sequentially, or 
simultaneously. Sham controls were treated with 1X PBS. Treatment groups included: 1) 
single/monocolonization with only one B. fragilis strain (NTBF or ETBF), 2) sequential 
colonization with initial strain at day 0 and challenge strain at day 3 (NTBFàETBF or 
ETBFàNTBF), and 3) simultaneous colonization with both B. fragilis strains 
(NTBF+ETBF). Fecal colonization of the initial strain was confirmed for all sequentially 
treated mice prior to administration of the challenge strain. ΔPSA NTBF denotes the 
isogenic PSA deletion mutant of B. fragilis NCTC 9343131. For co-infection colitis 
experiments, mice were sacrificed 2 weeks after infection with the initial bacterial strain 
in WT mice, at 2 to 4 weeks in Min mice for the microadenoma experiments, and at 12 
weeks in the Min mice for the macroadenoma experiments. For germ free (GF) 
monocolonization experiments, C57BL/6 GF mice were gavaged at 6 to 10 weeks old 
and sacrificed at both 2 weeks and 8 weeks post-colonization.  
For therapeutic treatment of SPF co-infected mice, mice were colonized with a 
single strain for 2 weeks (NTBF or ETBF). Fecal colonization of the initial strain was 
confirmed for all mice prior to administration of the second strain. At 2 weeks, mice were 
gavaged with NTBF (when pre-colonized with ETBF) or ETBF (when pre-colonized 
with NTBF) daily, for 9 days. Control NTBF or ETBF only mice were gavaged with 1X 
PBS. Mice were rested for 2 days after consecutive treatments and then sacrificed at 24 
days after initial strain gavage. The Johns Hopkins University Animal Care and Use 
Committee approved all experimental protocols. SPF mice were held in specific pathogen 
free conditions in accordance with the Association for the Assessment and Accreditation 
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of Laboratory Animal Care International. GF mice were bred in the gnotobiotic mouse 
facility at Johns Hopkins University Medical Campus, Baltimore, MD.  
 
Fecal Colonization and Mucosal Adherence 
 Mouse stools were weighed, homogenized (10-1 dilution), and serially diluted (10-
5, 10-6, 10-7) in sterile 1X PBS. At sacrifice, mouse distal colon tissue (~1 cm in length) 
was harvested, weighed, and washed twice (30 seconds, vortex setting 7) with 0.016% 
dithiothreitol (Thermo Scientific) in 1 ml of 1X PBS to quantitate bacteria that were 
tightly adherent to the mucosa. Washed tissue pieces were transferred to 350 µl 1X PBS, 
homogenized, and serially diluted (10-1, 10-2, 10-3). Dilutions of stool and colon tissue 
were plated onto BHI clindamycin agar and grown anaerobically for ~48 hours for 
determination of viable bacterial CFUs. Data are presented as B. fragilis CFUs per gram 
of stool or tissue.  
 
Quantitative RT-PCR 
 Distal colon whole tissue RNA was extracted using the Qiagen RNeasy Mini Kit 
according to manufacturer’s instructions. RNA (1 µg) was reverse transcribed to cDNA 
using the Superscript III Reverse Transcriptase kit (Invitrogen) according to 
manufacturer’s instructions. For each sample, two technical replicates, 1 µl of cDNA per 
reaction, were run with Taqman Gene Expression Mix. According to standard 
amplification protocols, samples were run on the 7500 Real-Time PCR System (Applied 
Biosystems) for 40 cycles. Primer/probe sets for respective cytokines were purchased 
from Applied Biosystems. Relative quantification (ΔΔCt) of indicated genes was 
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determined by subtraction of endogenous control 18S rRNA from all samples and then 
subtraction of normalized uninfected control values from colonized test values.  Fold 
change was determined by 2- ΔΔCt.  
 Fecal DNA was extracted using the Fast Stool DNA Kit (Qiagen). Whole tissue 
DNA was extracted using the QIAamp DNA Mini Kit using the pathogen detection 
protocol. Using the Taqman system, supplemented with bovine serum albumin, 100 ng of 
stool DNA was measured with three technical replicates per sample and 40 cycles (AB 
7500). Multiplex bft/16S qPCRs133,134 were run optimally at 58oC; singleplex 9343-Tn 
qPCRs were run optimally at 59oC132 (Supp. Table 1). Bacterial strain quantification was 
determined by standard curves developed from serially diluted (10-1) 9343 and 86-5443-
2-2 gDNA (using total genome copies from 108 to 102).  
 
Histology, Microadenoma, and Macroadenoma Counts 
 Colons were dissected, Swiss rolled, and fixed with 10% buffered formalin for 
~24 hours. Histology examination and scoring was done on hemotoxylin and eosin 
(H&E) stained 5 µm sections. Disease scoring was done as previously described by a 
pathologist (Dr. Sarah Beck)75. Swiss rolled H&E stained sections of MinApc716+/-  mice 
were examined for microadenomas throughout the distal colon by light microscope at 
20X magnification. At late time points, MinApc716+/- colons were flushed, opened, and 
fixed with 10% buffered formalin for ~24 hours. After fixation, colons were stained with 
methylene blue solution (0.2% in saline) (Sigma) for 1 hour. Macroadenomas were 
counted using a dissecting scope (Leica ES2).  
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Immunofluorescence and FISH Staining 
 Un-flushed colons of co-infected mice were fixed in formalin for 24 hours, 
suspended in saline, and paraffin-embedded (FFPE). Tissue sections were stained with 
Periodic acid-Schiff (PAS) to confirm mucus preservation. Deparaffinized histological 
sections (5 µm) were subjected to a standard IF protocol as follows: 1) initial block with 
1X PBS (5% goat serum, 1% BSA) for 1 hour at RT, 2) incubation overnight at 4oC with 
primary antibodies: adsorbed NTBF rabbit serum (1:100) and adsorbed ETBF rat serum 
(1:100), 3) two washes, 1X PBS, 4) incubation at RT for 1 hour with secondary 
antibodies: goat anti-rabbit AF488 (1:100) (Sigma, A-11034) and goat anti-rat AF568 
(1:100) (Sigma, A-1107), 5) two washes, 1X PBS, 6) incubation with DAPI 5 minutes, 7) 
two washes, dH2O, 8) mounted with ProLong Gold Antifade (Invitrogen) reagent, 9) 
cured for 48 hours before imaging with Zeiss LSM 780 confocal microscope. Rabbit 
serum generated to NTBF was graciously provided by Dr. Laurie Comstock (Harvard 
University). Rat serum generated to ETBF was commissioned by Covance Inc.  
 Successive sections were hybridized with a B. fragilis bacterial probe (IDT) 
(Supp. Table 1)135 and stained with DAPI. Probes were applied at a concentration of 2 
µM in pre-warmed hybridization buffer (900 mM NaCl, 20 mM Tris pH 7.5, 0.01% 
SDS). Slides were incubated at 46oC for 2 hours. Slides were washed three times for 5 
minutes with FISH wash buffer (215 mM NaCl, 20 mM Tris pH 7.5, 5 mM EDTA). 
Slides were washed in distilled water, dipped in 100% ethanol, and air-dried. Coverslips 
were mounted with ProLong Gold Antifade (Invitrogen) reagent. Slides were imaged 
with a Zeiss LSM 780 confocal microscope. Paired images were taken and analyzed 
under identical parameters. 
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LPL, Spleen, and MLN Isolations 
 Dissected distal colons (defined as everything distal of the proximal colon striated 
or feathered architecture) were flushed. Colons were cut to <0.5 mm pieces and washed 
in 1X sodium bicarbonate buffer supplemented with EDTA (2 mM), FCS (10%), HEPES 
(25 mM), and HBSS for 20 minutes at 37oC, three times. Tissues were digested in RPMI 
supplemented with FCS (5%), liberase (400 units/ml; Roche Diagnostic), and DNAse 1 
(0.2 mg/ml; Roche Diagnostic) for 30 minutes. Percoll gradient (20%, 40%, 80%) (GE 
Healthcare Life Science) separation was used to isolate mononuclear cells. Harvested 
spleen and MLNs were each pooled and digested in RPMI (5% FCS), with liberase and 
DNAse 1 for 30 minutes. Accu-Prep (Accurate Chemical) cell separation media was used 




For SPF and GF experiments, LPLs from individual colons, 4 to 5 mice per 
group, were isolated. Isolated mononuclear cells were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with FCS (5%) with Cell Stimulation 
Cocktail (containing protein transport inhibitors) (eBioscience) in 96-well plates for 4 
hours. Cells were washed with 1X PBS, stained for cell surface markers, fixed, and 
permeabilized. ICS was done for IL-17A, IFNγ, and Foxp3. Flow cytometry was 




Statistical Analysis           
  The nonparametric two-tailed Mann-Whitney U test was used to compare 
means of all treatment groups. A p value of <0.05 was denoted as significant. For 
correlation analysis, the nonparametric two-tailed Spearman test was used. An rs value of 















NTBF Subverts Inflammation and Adenoma Development 
 ETBF infection of specific pathogen free (SPF) C57BL/6 WT (Apc+/+) mice 
induces an acute, self-limiting inflammatory diarrhea and robust mucosal IL-17A 
response73,74. After 3 to 5 days, the mice recover from the diarrhea but maintain 
subclinical, chronic Th17-mediated colitis for about one year after infection74,76. As 
NTBF-derived PSA has been shown to be protective in the 2, 4, 6-trinitrobenzenesulfonic 
acid (TNBS) and Helicobacter hepaticus SPF experimental models of colitis129,136, we 
sought to disrupt ETBF-induced colitis by sequentially introducing NTBF followed by 
ETBF (NTBFàETBF: NTBF given first and ETBF given 3 days later) or by 
simultaneously introducing NTBF along with ETBF (NTBF+ETBF: NTBF and ETBF 
given at the same time) (Supp. Fig. 1 Colitis Protocol). The same co-infected treatments 
were replicated with the PSA mutant strain of NTBF (ΔPSA NTBF) (Supp. Fig. 2). Two 
weeks post-infection (p.i.), we found that both NTBFàETBF and ΔPSA NTBFàETBF 
treated mice exhibited a significant decrease in IL17A transcription in comparison with 
NTBF+ETBF or ETBF only control mice as measured by whole colon qRT-PCR (Fig. 
1A). However, both NTBFàETBF and ΔPSA NTBFàETBF treated mice exhibited 
increased IL17A expression levels compared to NTBF or ΔPSA NTBF monocolonization.  
Nonetheless, consistent with decreased inflammatory IL17A expression, NTBFàETBF, 
and to a larger extent ΔPSA NTBFàETBF mice, showed a decrease in histopathological 
inflammation and hyperplasia in comparison with ETBF only controls (Fig. 1B-C). 
These findings suggest that NTBF, irrespective of PSA expression, may offer protection 
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against Th17-driven colitis. 
A prior report indicated monocolonization of germ free (GF) mice with ΔPSA 
NTBF induces a pathogenic Th17 cell accumulation, a response suppressed by exogenous 
treatment with purified PSA130. Notably, in our SPF mice, there were no differences in 
whole tissue IL17A expression between NTBF and ΔPSA NTBF groups, either singly or 
sequentially treated, suggesting that the absence of PSA did not drive a 
microenvironment high in IL-17A (Fig. 1A). NTBF has been shown to induce CD4 T 
cells to produce IFNγ and IL-10, indicative of its putative role in contributing to the 
Th1/Th2 balance and restriction of inflammatory responses in the gut129,136,137. In 
evaluating cytokines typical of Treg and Th1 responses in our SPF infection model, there 
were no distinct increases in transcriptional expression of the genes encoding IL-10 or 
IFNγ in SPF mice monocolonized or co-infected with WT or ΔPSA NTBF; modest 
increases were observed in singly infected ΔPSA NTBF mice that were significant 
compared to monocolonized NTBF mice, although these results remained close to 
baseline representing less than a 2-fold increase (Fig. 1A). Long-term assessment of SPF 
mice colonized with WT NTBF yielded no changes in characteristic helper T cell 
cytokines (Supp. Fig. 3). These data suggest that within a more complex host (e.g. SPF), 
immune system balances already in place are not impacted by the introduction of PSA in 
the form of NTBF colonization. Protection from ETBF colitis is not mediated through the 
NTBF-derived PSA molecule.  
We next evaluated the role of NTBF in the context of ETBF tumorigenesis (Supp. 
Fig. 1 Microadenoma/Macroadenoma Protocol). ETBF infection of SPF Min (Apc+/-) 
mice induces rapid colon tumorigenesis with microadenoma (detected by microscopy) 
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onset at 5 days and quantifiable as early as 2 weeks, and visible macroadenomas noted as 
early as 4 weeks after colonization75. Consistent with the results of the colitis model, SPF 
Min mice infected sequentially (NTBFàETBF) showed a significant decrease in 
macroadenoma formation in comparison with NTBF+ETBF or ETBF only control mice 
at 12 weeks (Fig. 2A-B). There were no differences in macroadenomas noted between 
WT and ΔPSA NTBF treatment groups, either singly or sequentially treated. 
Furthermore, ΔPSA NTBF colonization of Min mice did not augment macroadenoma 
formation in Min mice not infected with ETBF, reinforcing the absence of a mucosal 
Th17 response following colonization with ΔPSA NTBF (Fig. 1A, Fig. 2A-B). When 
evaluating microadenomas at 2 to 4 weeks, we found that NTBFàETBF mice exhibited 
no significant reduction in counts and microadenoma morphology and size remained 
variable, consistent with ETBF controls. (Fig. 2C-D). Yet, it was observed that the 
blunting of visible macroadenomas was maintained at 8, 12, and 16 weeks p.i. (Supp. 
Fig. 4). Although these results suggest that tumor initiation between co-infected groups 
(sequential or simultaneous) is similar, the NTBF-mediated protection from tumor 
progression appears highly durable and suggests protection may be at the level of tumor 
growth versus tumor initiation. It should be noted that distinct outliers could be observed 
in Min mice that were sequentially treated, e.g. mouse #312 and mouse #238 produced 51 
and 10 macroadenomas, respectively (Fig. 2B & data inset), a finding that prompted us to 
evaluate the relative burden of each B. fragilis strain in individual mice. Both WT and 




PSA Does Not Impact B. fragilis Fecal or Mucosal Colonization  
 Within the GF mouse mucosa, B. fragilis was reported to specifically reside 
within the colonic crypts with PSA as the purported mediator of this colonization through 
the suppression of antibacterial Th17 responses130,138. Thus, in GF mice, ΔPSA NTBF 
exhibited diminished mucosal colonization in comparison with the PSA-competent 
parental strain (NTBF). This colonization deficiency was restored through treatment with 
exogenous PSA or IL-17A neutralizing antibodies130. We used fluorescence in situ 
hybridization (FISH) to localize B. fragilis in the mucosa of monocolonized SPF and GF 
mice. Both NTBF and ΔPSA NTBF strains were observed to colonize in the lumen and at 
the mucosal surface in SPF and GF mice, with a small subset visualized to reside in the 
mucus layer (Fig. 3A arrows). B. fragilis penetration into the mucus layer appeared 
patchy and limited, while a few instances of possible crypt invasion were also observed. 
In either housing condition, both bacterial strains exhibited the same colonization pattern. 
This finding is consistent with reports that B. fragilis can bind to, degrade, and utilize 
intestinal mucins as a nutrient source139–141. 
Because ΔPSA NTBF monocolonized GF mice were reported to display a 
significant decrease in the abundance of tissue-associated bacteria, suggestive of the PSA 
requirement for the close association of B. fragilis with the host mucosa130, the distal 
colon tissue and feces of SPF and GF monocolonized mice were homogenized and 
cultured to quantify viable CFUs of bacteria closely associated with the epithelium 
(mucosal colonization) and in the stool (See Methods). No differences in the viable 
bacterial burden were observed in the feces or the mucosa at early or late time points (2 
or 8wk) post-infection (Fig. 3B). Thus, PSA deficiency did not change bacterial burden 
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and localization, indicating that PSA does not routinely impact the parameters of B. 
fragilis niche occupation. Routine assessment of B. fragilis colonization in SPF mice also 
yielded similar fecal and mucosal colonization levels among NTBF, ΔPSA NTBF, and 
ETBF-treated mice (Supp. Fig. 5), with each strain achieving a similar colonization 
burden. 
 
Disease Outcome is Determined by an ETBF Critical Threshold 
ETBF monocolonization induces rapid lethality, within 3 days, in GF mice 
(129S6/SvEv74 and C57BL/6 (P. Fathi and C. Sears; unpublished data)). GF mice 
(129S6/SvEv) colonized with NTBF and subsequently exposed to ETBF survived ~2 
weeks, but ultimately succumb (S. Wu, B. Sartor, and C. Sears; unpublished data). 
Similarly, ETBF IL-17A-mediated colitis and tumorigenesis was significantly abrogated 
in SPF sequentially infected mice (Fig. 1-2). We investigated whether B. fragilis strain 
competitive exclusion could be playing a role in disease prevention. In viable bacterial 
colony screenings of stools harvested from WT NTBFàETBF or NTBF+ETBF treated 
mice, we found that one dominant strain was established, as early as 1 week after 
infection. NTBFàETBF mice became colonized predominantly with NTBF (90% of 
mice), while NTBF+ETBF mice became colonized predominantly with ETBF (100% of 
mice) (Fig. 4A). Using quantitative PCR (qPCR) to detect low-level colonization, the 
relative proportions of both B. fragilis strains were determined in the feces of co-infected 
mice. At 2 weeks p.i., WT NTBFàETBF and ΔPSA NTBFàETBF mice both showed 
NTBF dominance in the feces (defined as > 105 - 108 detected copies) (purple and orange 
circles, Fig. 4B), whereas NTBF+ETBF mice showed ETBF dominance in the feces 
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(green circles, Fig. 4B). Similarly, at > 3 months p.i., Min NTBFàETBF and ΔPSA 
NTBFàETBF mice exhibited NTBF dominance in the feces (purple and orange circles, 
Fig. 4D), whereas NTBF+ETBF mice exhibited ETBF dominance in the feces (green 
circles, Fig. 4D). Of note, we also observed that the high tumor-producing Min 
NTBFàETBF mice, #312 and #238, showed complete NTBF displacement, indicative of 
the capability for host strain replacement by ETBF with modification of disease 
trajectory. Strain quantification in distal colon mucosal tissue by qPCR mimicked the 
fecal results, although approached the limits of detection (not shown).  
 The consistency of the bacterial viability (Fig 4A) and the qPCR (Fig 4B and 
4D) measures of strain dominance suggest two points: 1) NTBF, given adequate time to 
colonize, prevents ETBF from establishing dominance; and 2) ETBF exhibits a 
competitive advantage over NTBF during simultaneous co-infection. The percentage of 
WT and Min mice sequentially infected (NTBFàETBF) and displaying a high NTBF 
copy number was 92.9% and 86.7%, whereas those with a high ETBF copy number was 
28.6% and 20.0%, respectively (Tables 1 and 2). These percentages exceed 100% 
because a subset of mice acquired high level colonization (> 105 copies) with both NTBF 
and ETBF, counter to a prior report138. The percentage of WT and Min mice 
simultaneously infected (NTBF+ETBF) with a high NTBF copy number was 44.4% and 
36.4%, whereas those with a high ETBF copy number was 100% and 90.9%, respectively 
(Tables 1 and 2). These data suggest that once a B. fragilis strain is established in the 
host, it is infrequently altered or supplanted by the introduction of another strain. Notably 
in our SPF model, we show that a secondary B. fragilis strain introduced through 
subsequent challenge has the ability to maintain persistent colonization (up to 4 months), 
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but at appreciably lower levels, on average, a thousand-fold less than the initial 
colonizing strain (Fig. 4B and D; Tables 1 and 2). We also observed that ETBF strain 
dominance was predictive of inflammatory and tumor responses. Strong positive 
correlations were observed between ETBF copy number with IL17A expression 
(rs=0.7469) and tumor development (rs=0.7899) (Fig. 4C and E). Of significance, in 
individual co-infected mice (NTBF+ETBF or ETBFàNTBF) when the critical disease-
triggering ETBF burden (~107 copies) was achieved, relatively high levels of NTBF co-
colonization (~105-106 copies) did not abrogate disease (* denotes individual mice with > 
105 copies of both ETBF and NTBF, Fig. 4B-E). Additionally, we observed the 
infrequent occurrence (2 out of 15 mice) of complete NTBF displacement by ETBF in 
long-term infected NTBFàETBF Min mice (purple circles: mouse #312 & #238, Fig. 
4D-E). Of note, these data points correspond to the high tumor-producers noted in Fig. 
2B.  
Collectively, these findings suggest that NTBF has the ability to prevent, yet not 
rescue, pathogenic ETBF from reaching disease-inducing levels within the host. Given 
the relatively high frequency of NTBF and ETBF co-colonization observed, we 
postulated that NTBF and ETBF may display distinct mucosal colonization patterns. 
Thus, we sought to identify the colonic locale of both B. fragilis strains, NTBF and 
ETBF, using immunofluorescence (Supp. Fig. 6). Our results suggest both NTBF and 
ETBF colonize the lumen and at the mucosal surface, with patchy mucus layer 
penetration (Fig. 4F top row) (Supp. Fig. 7). Due to lower level colonization of the non-
dominant strain leading to imaging limitations (4x104 bacteria per ml are required to 
visualize one bacterium per 400X magnification observation field) in co-colonized mice, 
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only the dominant B. fragilis strain could be clearly visualized. B. fragilis in either 
NTBF-dominant or ETBF-dominant co-infected mice colonized the distal colon with a 
similar pattern (Fig. 4F bottom row) (Supp. Fig. 7). 
 
Therapeutic Treatment with NTBF Fails to Disrupt ETBF Dominance and Disease  
 To further assess whether NTBF could abrogate disease in a therapeutic manner, 
WT mice were stably infected with ETBF for 2 weeks and then gavaged with NTBF 
daily, for nine days (ETBFàNTBFR) (Supp. Fig. 1 Probiotic Protocol). Mice were 
sacrificed after two days of rest from NTBF probiotic treatment. In a subset of 
ETBFàNTBFR mice (3 out of 5), we were able to introduce low-level stable 
colonization of NTBF with therapeutic treatment (Fig. 5A, red circles-mouse ID: 62, 61, 
59). Interestingly, low-level NTBF integration into stably colonized ETBF mice led to no 
impact seen on ETBF colonization or clinicopathology. Namely, ETBFàNTBFR mice 
exhibited small, contracted ceca containing blood clots and diminished cecal content, a 
response to cecal injury, comparable to ETBFàPBSR controls; cecum weights and 
splenomegaly (an indicator of chronic inflammation in our model) were indistinguishable 
between these groups (Fig. 5B-D). Consistent with our results regarding the 
establishment of strain dominance, even with repeated exposure to ETBF, 
NTBFàETBFR mice maintained the appearance of healthy ceca, displaying 
characteristic weight and content, with no noted spleen enlargement, comparable to 
ShamàPBSR and NTBFàPBSR controls (Fig. 5B-D). Of interest, although our previous 
experiments suggested that ETBF had the capability to oust stably colonized NTBF, in 
this series of experiments, we found that NTBFàETBFR mice (5 out of 5) did not 
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develop stable ETBF colonization (Fig. 5A, purple circles). Overall, these data are 
consistent with the results of our colitis and tumor experiments, suggesting that NTBF 
may only be beneficial as a preventative measure.  
 
NTBF Modulation of the Immune System  
To further examine whether NTBF modulates immune responses in SPF mice, 
both WT and Min mice were colonized with NTBF or ΔPSA NTBF for 2 weeks. For this 
experiment, the lamina propria was sampled specifically from the distal colon, the colitis 
and tumor-prone locales in the WT and Min ETBF models. Comparisons of Sham, 
NTBF, and ΔPSA NTBF mice yielded unchanged IL-17A+, Foxp3+, or IFNγ+ T cell 
populations as well as IL-17A+ Foxp3+ lymphocyte populations whether analyzed by 
percentage or cell density (Fig. 6, Supp. Fig. 8: filled circles=WT; open circles=Min). 
Though the colon lamina propria represents the anatomical site most reflective of and 
meaningful to the immune responses initiated by intestinal microbial exposure, similar 
results were also obtained in the mesenteric lymph node and spleen (Supp. Fig. 9). These 
data were further consistent with the analysis of whole tissue transcriptional expression of 
IL17A, IL10, and IFNG cytokines in SPF WT mice (Fig. 1A).  
We extended these results to GF WT mice (6 to 8 weeks of age) that were 
monocolonized with NTBF or ΔPSA NTBF for either 2 or 8 weeks. We first examined 
both the splenic morphology and histological sections of control and monocolonized GF 
and matched SPF mice. Spleens from mice across all treatment groups and housing 
backgrounds exhibited a normal size and weight, while histological sections revealed 
normal appearing lymphoid development in the form of well-defined follicles comprising 
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the white pulp (Supp. Fig. 10). Surprisingly, flow cytometric analysis of the GF colon LP 
yielded no differences in the accumulations of Th17, Treg, Th1, or total IL-17A 
populations between WT and ΔPSA NTBF-colonized mice at early or late time points as 
reflected by absolute cell number (cell density) (Fig. 7A). In parallel, we analyzed the 
transcription of cytokines of functional relevance to the described immune cell 
populations. Again surprisingly, we were unable to observe any differences in the 
stereotypical Th17 or Treg cytokines, IL-17A and IL-10, in WT versus ΔPSA NTBF-
treated mice. However, we did observe that monocolonized mice exhibited increased 
IL17A expression compared with un-infected GF controls at 2 weeks but not at 8 weeks. 
We also evaluated the gene expression of characteristic Th1 and Th2 cytokines, IFNγ and 
IL-4, and found no differences among groups (Fig. 7B). Accumulations in IL-17A-
producing or IFNγ-producing γδ T cells were also comparable between groups (Supp. 
Fig. 11). However, the total IFNγ-producing cell population was significantly less in 
mice colonized with ΔPSA NTBF for two weeks and then significantly greater at 8 weeks 
when compared to PSA-sufficient NTBF (Fig 7A), suggesting a possible role of PSA in 
maintaining the balance of interferon in the GF host. However, this result was not 
confirmed by whole colon tissue expression analysis (Fig. 7B). Taken together, 
colonization with PSA-sufficient NTBF does not modulate SPF or GF host immune 
responses in a manner protective against ETBF-induced colitis. 
 
ETBF Secretes an Intraspecies Inhibitory Molecule 
 Competition for limited resources can be broadly categorized into scramble 
competition, where one organism rapidly utilizes a limiting resource with no direct 
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contact with a competing organism, or contest competition, where antagonistic 
interactions occur between competing organisms142. Such mechanisms are vital to 
microbial establishment and persistence. Our data show that ETBF consistently 
outcompetes NTBF during simultaneous co-infection in mice (Fig. 4A, B, and D). Many 
factors, including growth rate, nutrient utilization, colonization factors, and possible 
antimicrobial secretion likely contribute to ETBF fitness142.  
To evaluate strain differences in growth and nutrient utilization, bacterial growth 
and recovery was monitored. Individually, NTBF and ETBF strains exhibited similar 
growth rates (Fig. 8A). Intriguingly, when strains were co-cultured at equal starting 
points, the percent recovery of NTBF was severely diminished after 24 to 48 hours (Fig. 
8B). Finally, when strains were co-cultured at varying input ratios for either 24 or 48 
hours, NTBF could only be recovered when it comprised the majority of the input strain 
(Fig. 8C). Since we did not observe any individual growth differences among strains, we 
hypothesized that ETBF was secreting an antimicrobial compound leading to NTBF 
growth inhibition. 
Bacteriocins differ from classical antibiotics in that they are synthesized 
ribosomally and have a narrow killing spectrum, acting on closely related species or on 
variants of the same species95. We carried out agar diffusion assays with cell-free ETBF 
supernatants harvested from stationary phase cultures and found that, indeed, ETBF-
derived culture supernatants could inhibit the growth of NTBF and other closely related 
strains in a BFT-independent fashion. Protease treatment with trypsin, proteinase-K, and 
heat inactivation at 100oC eliminated the activity of the ETBF supernatant, indicating that 
the inhibitory molecule is likely a protein (Fig. 8D, Supp. Fig. 12). Chatzidaki-Livanis et 
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al. recently showed membrane attack complex/perforin (MACPF) bacteriocidal activity 
among B. fragilis strains143. Interestingly, ETBF carry an identical copy of the identified 
Bacteroidales-secreted antimicrobial protein 1 (BSAP-1) gene originally characterized in 
B. fragilis strain 638R. Indeed, qRT-PCR analysis revealed that BSAP-1 was highly 
expressed in ETBF but not in NTBF (Supp. Fig. 13A). Therefore, the secretion of a pore-
forming molecule is one likely candidate contributing to ETBF's competitive advantage 
over NTBF, leading to the dramatic growth inhibition of NTBF.  
Recently, a novel Bacteroides polyssacharide utilization locus regulating species 
saturation was described138. Mutations in this commensal colonization factor locus (ccf) 
altered B. fragilis niche occupation in mice, becoming permissive to challenge 
colonization by the same species. We hypothesized that differential gene expression in 
ccfA and ccfB, the sigma/anti-sigma factor pair, would contribute to an ETBF competitive 
advantage. Distal colon tissue ccfA and ccfB expression levels were similar between 
NTBF and ETBF-monocolonized mice, suggesting that ccf gene regulation was similar 
between both B. fragilis strains (Supp. Fig. 13B). This result does not rule out 
differential gene expression occurring when competing strains are simultaneously in 





Basis for NTBF Probiotic Usage 
The colon symbiont, NTBF, was first discovered to influence gut immune 
homeostasis in germ free mice by directing lymphoid organogenesis, restoring the splenic 
CD4+ T cell compartment, and rectifying the Th2-skewed imbalance137,144. Indeed, 
purified spleen CD4+ T cells from ΔPSA NTBF mice showed an overproduction of IL-4 
and diminished IFNγ as measured by ELISA; the reverse was seen in mice colonized 
with WT NTBF137. After this initial groundbreaking study, the functional role of the PSA 
molecule has been further expanded upon. GF mice monocolonized with NTBF or treated 
orally with purified PSA initiate Foxp3+ Treg accumulation in the colon LP and MLN129. 
This accumulation is accompanied by Treg-derived IL-10 production as measured by 
LPL ICS and by whole colon tissue and purified CD4+ Foxp3+ T cell (MLN) qRT-
PCR129. Regarding inflammatory development, ΔPSA NTBF GF mice exhibit a noted 
Th17 cell accumulation in the colon LP, accompanied by increased IL17A and RORC 
transcription as measured by qRT-PCR in purified CD4+ T cells of the MLN130. This 
Th17 signature even interferes with the strain’s ability to establish on the colonic mucosa, 
its main ecological niche130. Amazingly, this immune phenotype and colonization defect 
is completely reversed when ΔPSA NTBF mice are exogenously treated with purified 
PSA, evidence of a crucial immunomodulatory function for PSA in mucosal immune 
system development130.  
Certainly, previous studies have shown that these effects translate over to a more 
complex host 129,136. Rag-deficient SPF mice co-infected with WT NTBF or treated with 
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purified PSA were protected from CD45RBhigh T cell transfer/Helicobacter hepaticus-
induced colitis, whereas ΔPSA NTBF co-infected or vehicle-treated mice were not136. 
Furthermore, SPF mice treated orally with PSA were also protected from a chemically-
induced (TNBS) form of colitis, and this was attributed to the PSA inducement of Foxp3+ 
Treg MLN expansion and IL-10 production as measured by expression in whole colon, 
whole MLN, and purified CD4+ T cells of the MLN129,136. In the prevailing working 
model, NTBF is thought to promote immune tolerance by producing outer membrane 
vesicles (OMVs) containing PSA, which are then recognized by dendritic cells (DC) via 
TLR2145. This gives rise to DC-derived IL-10 production which promotes Treg 
responses, which produce additional IL-10, leading to the suppression of T helper cell-
derived inflammation145.  
To discern the probiotic potential of NTBF in gut health, we studied how NTBF 
impacted an ETBF-driven disease model of colitis and tumorigenesis. Specific pathogen 
free C57BL/6 WT and MinApc716+/- mice were used in a NTBF and ETBF co-infection 
model where mice were sequentially or simultaneously treated. We showed that NTBF 
limited ETBF disease severity, significantly reducing the IL-17A-mediated inflammatory 
signature and blunting the development of colon tumors. However, this finding was 
limited to mice that had been sequentially infected, receiving NTBF first and ETBF three 
days later (NTBFàETBF), suggesting the potential of NTBF prophylaxis. Mice 
simultaneously infected (NTBF+ETBF) or sequentially infected, where ETBF was given 
first and NTBF three days later (ETBFàNTBF), continued to exhibit severe disease, 
even in mice who became co-colonized with comparable levels of NTBF and ETBF (Fig. 
4B-D). Notably, although prophylactic NTBF blunted pro-inflammatory IL-17A gene 
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expression, it failed to fully block IL-17A production in the colitis setting (Fig. 1A). 
Consistent with this finding, we observed the development of microadenomas in 
NTBFàETBF mice that did not progress to visible macroadenomas, even after 16 weeks 
(Fig. 2, Supp. Fig. 4). Though our results show that NTBF partially subverted both 
ETBF-induced colitis and tumorigenesis, surprisingly, we discovered that this effect was 
not dependent on NTBF-encoded polysaccharide A (PSA). Namely, we observed disease 
prevention in both mice co-infected with the wild type NTBF parental strain as well as in 
mice co-infected with the PSA deficient NTBF strain.  
We demonstrated that SPF mice singly colonized with WT or ΔPSA NTBF 
displayed neither an inherent difference in inflammatory or regulatory T cell levels in the 
LP (IL-17+, IFNγ+, Treg), nor differences in cytokine expression in whole colon tissue 
(IL17A, IFNG, IL10), contrasting with the studies described above. Geis et al. recently 
described a mechanism by which Foxp3+ regulatory T cells initiated the inflammatory 
Th17 response during ETBF infection146. We analyzed the accumulation of this IL-17A+ 
Foxp3+ T cell population and found no differences among groups. Altogether, these data 
demonstrate that the absence of PSA neither diminish NTBF’s protective capability, nor 
primes SPF mice for inflammatory Th17 polarization.  
It is well established that gut immune homeostasis in SPF mice is vastly different 
from that of GF mice, which exhibit many immune deficiencies147,148. Accordingly, we 
evaluated the impact of NTBF colonization in GF mice. In contrast to previous 
reports137,149, we did not observe a PSA-inducement of lymphoid organogenesis in the 
spleen. Furthermore, to our surprise, PSA competent NTBF did not affect the 
accumulation of LP Treg or Th1 cellular subsets or alter the accumulation of Th17 cells 
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observed in ΔPSA NTBF colonized mice at early (2wk) or late (8wk) time points. The 
parallel assessment of IL10, IFNG, IL4, and IL17A cytokine expression also yielded no 
differences between groups; yet, suggesting that bacterial colonization alters the immune 
system of GF mice, monocolonized mice with either WT or ΔPSA NTBF showed 
increased IL17A gene expression compared with uninfected controls at an early time 
point. Beyond the CD4+ T cell compartment, there were also no differences seen in the 
recruitment of IFNγ-producing or IL-17A-producing γδ T cells. Although we observed an 
accumulation in total IFNγ-producing cells in ΔPSA NTBF mice at 8 weeks, this finding 
contrasted with previous reports describing the reverse, where PSA-competent NTBF 
induced IFNγ and reduced IL-4 production in stimulated splenic T cells137. Finally, in 
contrast with a previous study, ΔPSA NTBF-colonized SPF and GF mice did not exhibit 
diminished mucosal colonization levels or differential mucosal niche occupation.  
A key feature of our findings is that they represent the analysis of cells and tissues 
isolated from the colons of mice on the C57BL/6 background. The earliest discoveries 
showing NTBF-directed immune system maturation and lymphoid development were 
made in the spleens of GF Swiss-Webster mice obtained from Taconic136,137. Importantly, 
our GF C57BL/6 mice were bred and maintained in sterile isolator conditions in house at 
JHU. Previous analyses of B. fragilis niche occupation and species resistance also utilized 
GF Swiss-Webster mice138,139. Finally, because we studied direct NTBF colonization in 
SPF and GF mice, we cannot exclude the role of purified PSA in directing gut immune 
development. For disease modeling, these data suggest the importance of sampling the 
most clinically relevant experimental sites, as well as taking into account the effects of 
differences in mouse strain and housing conditions.  
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Mucosal Niche and Barrier Development 
Another important aspect of disease control in the gut comes from the anatomical 
separation of the luminal contents from colon epithelial cells that is maintained by gel-
forming mucins. In mice, similar to humans, the mucus layer of the colon consists of an 
impermeable, firm inner layer (~50 µm thick) devoid of bacteria and a loose outer layer 
(~100 µm thick) containing high numbers of bacteria150. Bacterial penetration and 
persistence within the inner mucus layer could be indicative of a dysbiosis contributing to 
disease.  
It is possible that the resident microbiota may temper the effects of colitis. For 
instance, ETBF induces rapid lethality in GF mice74, while GF mice colonized with 
NTBF prior to ETBF exposure, exhibit extended survival (S. Wu, B. Sartor, and C. Sears; 
unpublished data). Similarly, Chiu et al. showed that NTBF colonization of GF mice 
ameliorated DSS-induced colitis151. Although we did not observe a direct immunological 
or anti-inflammatory component to NTBF colonization, we hypothesize that NTBF’s 
presence in the host can act as an anatomical barrier from pathogenic organisms present 
in the gut lumen. In our model, the pattern of colonization burden in NTBFàETBF 
sequentially treated mice showed clear evidence of NTBF competitive exclusion of 
ETBF, likely diminishing epithelial cell damage or bacterial invasion that could be 
induced by the latter. In contrast, NTBF+ETBF simultaneously treated mice typically 
exhibit competitive exclusion of NTBF, limiting any defense against ETBF disease. In 
contrast to the results of Lee et al., we found that B. fragilis competitive exclusion was 
not absolute138 and, in fact, 7-21% of NTBFàETBF mice, 20% of ETBFàNTBF mice, 
and 27-44% of NTBF+ETBF mice displayed high level (> 105 CFU/100 ng) fecal co-
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colonization (Tables 1 and 2). Persistent colonization (up to 4 months) with a B. fragilis 
challenge strain was consistently observed in our mice, with even a few instances of 
complete NTBF displacement observed in NTBFàETBF mice. In our experiments, we 
found that NTBF and ETBF both localize to the mucosal surface, with patchy bacterial 
mucus penetration observed. Contrasting with previous data, we did not observe any 
colonization defects or alternative localization patterns of the mutant PSA NTBF strain, 
suggesting that PSA plays a negligible role in the bacterium’s colonization of the gut.  
Lending credence to the microbiota’s role in protective barrier formation, one can 
also look to recent developments in the field of glycobiology. Johansson et al. have 
documented the inadequate properties of the germ free mouse colon mucus layer, 
characterized by inner mucus permeability, mucin oligossacharide alteration, and Muc2 
deficiency152. Only after the conventionalization of GF mice with colonized cecal 
contents from mice with well-developed mucus layers, does the mucus fully develop its 
proper abundance and spatial organization of gel-forming mucins along with its 
characteristic inner layer impenetrability at 6 weeks152. Interestingly, Johansson et al. 
found shifts in the microbial communities of the mucus during mucus layer development, 
most notably a peak in the Firmicutes at 2 weeks followed by a transient shift to the 
Bacteroidetes (including Bacteroides genera) at 4 weeks152. This finding is suggestive of 
an integral role for Bacteroides in mucus maturation in the gut. The mucin attachment 
and degradation capabilities of some bacteria (including Bacteroides fragilis), which 
allow for close mucosal association, may have developed as a host-selective measure to 
retain beneficial microbes at specific locales. It will be fascinating to uncover the 
bacteria-driven mechanisms of host mucus maturation and development.  
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B. fragilis Fitness 
Bacterial fitness factors may be possible mechanisms contributing to the 
establishment of strain dominance. Monitoring of individual NTBF and ETBF strain 
growth did not suggest any differences in nutrient utilization strategies and differential 
expression of colonization factor genes was not observed. However, it has been shown 
that type VI secretion (T6S), the direct injection of effector proteins into the membrane of 
a target organism, is a way that bacteria can maintain competitiveness, with a widely 
conserved T6SS (T6S system) locus observed in the Bacteroidetes phylum. Indeed, the 
T6SS of B. fragilis has been shown to be effective against the closely related B. 
thetaiotaomicron and against other B. fragilis strains153,154. Hecht, et al. recently 
identified a differentially encoded effector-immunity region of this T6S locus that 
determines this intraspecies competition155. In a SPF co-infection mouse model of ETBF 
(ATCC43858) DSS colitis, NTBF protected against disease, whereas an NTBF mutant in 
a crucial T6S component (ΔtssC), did not. NTBF T6S was able to abrogate disease by 
diminishing the colonization of pathogenic ETBF, and thus diminishing the 
enterotoxigenic burden in the host. In our model, T6S may be another pivotal means by 
which NTBF precludes ETBF disease.  
We did observe the ETBF-specific secretion of a bacteroicin-like molecule with 
inhibitory activities on NTBF and other closely related strains, in a toxin-independent 
fashion. Easily harvested from culture supernatants, it appears that ETBF naturally 
produces this molecule in an unprovoked manner. Due to evidence of high BSAP-1 
expression levels in ETBF in vitro, we suggest that BSAP-1, a membrane attack 
complex/perforin, is a likely candidate in ETBF’s broad inhibitory actions on other 
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strains contributing to its own survival. We hypothesize that both timing and order, in 
addition to the secretion of inhibitory molecules in a non-discriminate fashion, 
contributes to B. fragilis competition dynamics.  
 
Clinical Framework for Therapeutic Treatment 
ETBF carriage in healthy, asymptomatic people is quite common with a recent 
study showing that 40% of individuals (6 out of 15 subjects) in Boston, MA, carried 
ETBF in their feces63. Yet clinically, ETBF is known as an etiologic agent of acute 
diarrhea in children and adults and is also highly associated with active IBD62,133,156.  
Recently, our group and others have shown that ETBF detection is highly associated with 
CRC cases, suggesting that ETBF colonization is a risk factor for CRC 
development133,157. Boleij et al. compared bft gene detection in CRC patient mucosa 
(n=49) with healthy control mucosa (n=49) undergoing routine outpatient colonoscopies, 
showing left colon detection rates 85.7% and 53.1% (p=0.03) and right colon detection 
rates 91.7% and 55.5% (p=0.04), respectively133. Moreover, bft detection showed an 
increasing trend moving from early to late stage CRC, 72.7% and 100% detection, 
respectively (p=0.09)133.  
Thus, we evaluated the possible remedial effect of NTBF on pre-existing ETBF 
disease. Therapeutic treatments of stably colonized ETBF mice with NTBF 
(ETBFàNTBFR), failed to abrogate disease severity. However, we did show evidence of 
introduction of this non-pathogenic NTBF strain into a subset of mice (3 out of 5). These 
findings are mimicked in the fecal microbial transplantation (FMT) literature in humans, 
showing that durable strain recipient replacement or steady coexistence (in 50.7 + 10.1% 
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of shared species) (up to 3 months) of both donor and recipient strains can be achieved, 
even without antibiotics prior to or during treatment158. However, microbiome resistance 
does occur. In 2 out of 5 ETBFàNTBFR mice, NTBF could not establish within the host. 
Similarly, in the clinical setting, in 1 of the 3 recipients of the same donor at 3 months 
post-FMT, only 12% of donor strain populations were detected, versus 46.1% and 56.6% 
in the remaining patients158. Such findings stress the importance of longitudinal clinical 
translational studies coupled with bioinformatics approaches as probiotic-recipient or 
donor-recipient compatibility and pre-existing disease states are likely to become salient 
in the field of bacterial biotherapeutics.  
We demonstrate a method by which non-toxigenic Bacteroides fragilis offers a 
preventative health benefit to the host that is not reliant on polysaccharide A or on direct 
host immune system modulation. Interestingly, the culturing of mucosal biopsies revealed 
that PSA-harboring human isolates of B. fragilis are not found more frequently at non-
inflamed sites versus inflamed sites in IBD patients (CD, p=0.68; UC, p=1.0), nor are 
PSA strains more often detected in healthy controls versus IBD patients (p=0.73)159. 
Thus, it seems unlikely that this polysaccharide will be the foremost determining factor of 
patient health. In terms of real world therapeutic applications, it appears that the order in 
which the host sees either NTBF or ETBF, the specific B. fragilis strains being 
introduced to and already existing in the recipient, and further, yet uncharacterized 
bacterial fitness factors are likely crucial to determining the overall disease outcome. 
Further research must be done to determine the proportions, diversity, and impact, down 
to the strain level, of the ideal gut microbiome for individual patients. Numerous clinical 
isolates of Bacteroides species have documented bacteriocin production and 
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sensitivity96,97. The diversity of these responses points to the complexity of microbial 
niche establishment and also lays the basis for the engineering of probiotic organisms to 
exploit advantageous fitness factors. For instance, Hillman et al. have developed a 
patented replacement therapy for Streptococcus mutans that induces dental caries via 
lactic acid production. S. mutans recombinant strain BSCE-LI lacks the Idh gene (lactate 
dehydrogenase) and secretes a potent bacteriocin, mutacin 1140, effective at actively 
displacing naturally occurring S. mutans in the oral cavity, increasing the pH and 
diminishing the development of tooth decay160. It can be envisioned that such 
bioengineering of beneficial gut microbes can be achieved, as more genetic tools become 
available. In diseases with protracted etiology, such as CRC, it is possible that the mere 
introduction of beneficial or non-pathogenic bacterial species or strains could work to 
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Supplemental Figure 1: Schematic of SPF mouse co-infection experiments. Mice 
received peroral antibiotic water ad lib for 5 to 7 days prior to initial bacterial infection. 
Sequentially infected mice received secondary strains on day 3. Simultaneously infected 
mice received both strains on day 0. Fecal colonization of the initial strain (day 0) was 
confirmed for all sequentially treated mice prior to administration of the challenge strain. 
For colitis experiments, mice were sacrificed 2 weeks post initial strain infection (WT), 
microadenoma experiments at 2 to 4 weeks (Min), and macroadenoma experiments at 12 
weeks (Min). For ‘probiotic’ treatment experiments, mice were colonized with single 
strains for 2 weeks (NTBF or ETBF). At 2 weeks, mice were gavaged with NTBFR (pre-
colonized with ETBF) or ETBFR (pre-colonized with NTBF) daily, for nine days. Control 
NTBF or ETBF only mice were gavaged with 1XPBS (PBSR). Mice were rested for two 
days after consecutive probiotic treatments and then sacrificed (24 days after initial strain 
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Supplemental Figure 2: Confirmation of PSA-competent and PSA-deficient NTBF 
strains. gDNA was extracted from NTBF and ΔPSA NTBF grown from single colony. 
Primer sets 1 (PSA flanking) and 2 (PSA) were used to confirm the PSA-mutant strain. 
ΔPSA NTBF was not amplified with primer set 2. NTC = no template control. Primer 





















Figure 1. PSA-competent and PSA-deficient NTBF incompletely reduce 
inflammatory responses. A-C SPF WT mice were inoculated sequentially 
(NTBFàETBF) (ETBFàNTBF) or simultaneously (NTBF+ETBF) and sacrificed 2 
weeks later. Distal colon tissue was harvested for whole tissue qRT-PCR. The remaining 
colon was reserved for FFPE. Bars indicate median and interquartile range. Data are from 
3 separate experiments with 3 to 7 mice per test group. A WT and ΔPSA NTBFàETBF 
mice exhibit significant blunting of IL17A expression in comparison with NTBF+ETBF, 
ETBFàNTBF, and ETBF controls, although IL17A expression remains significantly 
elevated in NTBFàETBF vs NTBF alone mice. IL10 and IFNG expression was similar 
between WT and ΔPSA NTBF co-infected treatment groups. An increase in IL10 and 
IFNG was observed in ΔPSA NTBF singly colonized mice, compared to PSA-sufficient 
NTBF, but remained close to baseline (< 2 fold increase). B Disease scores (additive 
hyperplasia and inflammation) of FFPE H&E sections. WT and ΔPSA NTBFàETBF 
mice exhibit a lower disease score compared with ETBF controls. C Representative H&E 










Figure 1:  PSA-competent & PSA-deficient NTBF incompletely 
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Supplemental Figure 3: IL17A, IL10, IFNG, and IL4 expression determined by colon 
whole tissue qRT-PCR at 17, 24, and 45 days after NTBF infection. NTBF-colonized 
SPF mice exhibit no changes in total IL17A, IL10, IFNG, and IL4 expression at early or 
late time points. Bars indicate median and interquartile range. Data shown are from 1 
independent experiment with 4 to 5 mice per time point. Mice were compared to their 
























































































































































Figure 2. PSA-competent and PSA-deficient NTBF similarly blunt tumorigenesis. A-
D SPF Min mice were inoculated sequentially (NTBFàETBF) or simultaneously 
(NTBF+ETBF). Mice were sacrificed at 12 weeks (macroadenomas) or 2 to 4 weeks 
(microadenomas). Bars indicate median and interquartile range. Data shown are from 3 
separate experiments with 3 to 4 mice per test group. A Images of representative 
methylene blue-stained distal colons. NTBFàETBF and ΔPSA NTBFàETBF mice 
display decreased tumor development compared with NTBF+ETBF and ETBF control 
mice. B Quantification of tumors from individual mice. Macroadenoma counts are 
recorded for the entire colon. Both WT and ΔPSA NTBFàETBF mice exhibit significant 
blunting of tumorigenesis in comparison with NTBF+ETBF and ETBF controls. Inset 
shows colon images of NTBFàETBF high tumor producers: mouse #312 and mouse 
#238. Macroadenoma numbers were similar between WT and ΔPSA NTBF treatment 
groups. C H&E colon sections displaying microadenoma histopathology of 
NTBFàETBF and ETBF only treated mice. D Quantification of microadenomas from 
individual mice. NTBFàETBF mice do not display a significantly lower microadenoma 
burden compared with ETBF control mice. 
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Figure 2: PSA-competent & PSA-deficient NTBF similarly blunt 















































Figure 2: PSA-competent & PSA-deficient NTBF similarly blunt 

















































Supplemental Figure 4: After strain establishment, NTBF protection against 
macroadenoma initiation is durable. Formalin-fixed, methylene blue-stained colons of 
NTBFàETBF mice and ETBF only control mice were counted for macroadenomas at 8, 
12, and 16 weeks after initial infection. Data shown at 8 and 16 weeks are from 1 
independent experiment (2 to 7 mice per treatment group). Data shown at 12 weeks 
represents a compilation of 3 independent experiments as shown in Figure 2B (3 to 4 
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Figure 3. PSA does not impact B. fragilis niche occupation. A-B SPF and GF mice 
were monocolonized with WT or ΔPSA NTBF for 2 or 8 weeks. Mouse colons were 
unflushed, fixed in formalin, and FISH-stained: DAPI=blue, Bacteroides fragilis 16S 
probe=red. A Representative FISH-stained mouse colons (2wk p.i.); images taken at 40X. 
Insets show images taken at 63X. WT and ΔPSA NTBF colonize both the lumen and at 
the mucosal surface with patchy mucus penetration (examples are shown with arrows). 
The presence or absence of PSA does not affect the colonic niche of NTBF. B Stool and 
mucosal colonization of mice inoculated with WT or ΔPSA NTBF. PSA does not impact 
fecal or mucosal NTBF colonization. Bars indicate median and interquartile range. Data 




































































Supplemental Figure 5: NTBF and ETBF exhibit similar fecal and mucosal colonization 
burden in mice. SPF WT and SPF Min mice were colonized with various B. fragilis 
strains: NTBF, ΔPSA NTBF, and ETBF. In WT mice, stool colonization was evaluated at 
3 days and 2 weeks p.i. and mucosal colonization at 2 weeks terminal sacrifice. In Min 
mice, stool colonization was evaluated at 3 days (NTBF and ΔPSA NTBF only) and 12 




































































Figure 4. Bacterial strain dominance determines inflammatory and tumor 
responses. A Viable colony forming unit (CFU) percentages of NTBF and ETBF strain 
detected in stools harvested 1 week p.i. in SPF WT mice. Isolated B. fragilis colonies (up 
to 30) cultured from stool homogenates were randomly selected and screened by strain-
specific PCR. In 9 of 10 NTBFàETBF mice, only NTBF was detected; in 1 of 10, both 
NTBF and ETBF were detected. In 3 of 3 NTBF+ETBF mice, only ETBF was detected. 
Strain dominance is established early. B-E Strain quantification as measured by fecal 
qPCR at 2 weeks (SPF WT) or 12-16 weeks (SPF Min) and presented in the order of 
NT/ET: lo/hi, hi/hi, or hi/lo. Low = 101 < 105 copies. High = >105 - 108. Circles represent 
individual mice; triangles represent median IL17A expression or median tumor counts 
(see right vertical axis). * = mice with hi/hi co-colonization levels. B Strain quantification 
in WT co-infected mice. C Correlation of IL17A gene expression with ETBF copy 
number in WT mice. D Strain quantification in Min co-infected mice. E Correlation of 
tumor number with ETBF copy number in Min mice. F Representative IF staining in SPF 
(WT or Min) mice (2-4wk p.i.); images taken at 40X. Insets show images taken at 63X. 
Top row: Both NTBF and ETBF colonize the lumen and at the mucosal surface with 
patchy mucus penetration (examples are shown with arrows). Bottom row: Co-colonized 
mice, either NTBF-dominant (NTdom) or ETBF-dominant (ETdom). 
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Figure 4: Bacterial strain dominance determines inflammatory  & tumor 
responses 




























































































































































Table 1. Stool copy numbers of NTBF and ETBF detected in SPF WT mice by 
treatment group at 2 weeks. Protocol described in Methods. Results are depicted as 
percent total (%) of colonized mice out of the total treatment group. Classification: Low 























Table 1: B. fragilis strain quantification in WT mice 
NTBF Only ETBF Only
Low / High                    
(101- <105) / (>105-108)           
High / Low                      
(>105-108) / (101- <105)        
High / High              
(>105-108) / (>105-108)
High            
(>105-108)
High            
(>105-108)
NTBF 0.0%(0/13) 0.0%(0/13) 0.0%(0/13) 100%(13/13) 0.0%(0/13)
NTBFèETBF 7.1%(1/14) 50.0%(7/14) 21.4%(3/14) 21.4%(3/14) 0.0%(0/14)
ΔPSA 
NTBFèETBF 0.0%(0/11) 27.3%(3/11) 0.0%(0/11) 72.7%(8/11) 0.0%(0/11)
ETBFèNTBF 80.0%(4/5) 0.0%(0/5) 20.0%(1/5) 0.0%(0/5) 0.0%(0/5)
NTBF+ETBF 22.2%(2/9) 0.0%(0/9) 44.4%(4/9) 0.0%(0/9) 33.3%(3/9)
ETBF 0.0%(0/12) 0.0%(0/12) 0.0%(0/12) 0.0%(0/12) 100%(12/12)
NTBF / ETBF Co-Colonization
Percent total (# colonized/total mice) 
TABLE 1. NTBF and ETBF strain quantification (qPCR) in stool of SPF WT mice persistently infected 




Table 2. Stool copy numbers of NTBF and ETBF detected in SPF Min mice by 
treatment group at 12 to 16 weeks. Protocol described in Methods. Results are depicted 
as the percent total (%) of colonized mice out of the total treatment group. Classification: 
























Table 2: B. fragilis strain quantification in Min mice 
NTBF Only ETBF Only
Low / High                    
(101- <105) / (>105-108)           
High / Low                      
(>105-108) / (101- <105)        
High / High              
(>105-108) / (>105-108)
High            
(>105-108)
High            
(>105-108)
NTBF 0.0%(0/5) 0.0%(0/5) 0.0%(0/5) 100%(5/5) 0.0%(0/5)
NTBFèETBF 0.0%(0/15) 66.7%(10/15) 6.7%(1/15) 13.3%(2/15) 13.3%(2/15)
ΔPSA 
NTBFèETBF 0.0%(0/5) 80.0%(4/5) 0.0%(0/5) 20.0%(1/5) 0.0%(0/5)
NTBF+ETBF 18.2%(2/11) 9.1%(1/11) 27.3%(3/11) 0.0%(0/11) 45.5%(5/11)
ETBF 0.0%(0/7) 0.0%(0/7) 0.0%(0/7) 0.0%(0/7) 100%(0/7)
Table 2. NTBF and ETBF strain quantification (qPCR) in stool of SPF Min mice persistently infected with 
B. fragilis by different inoculation protocols at 12 to 16 weeks
Percent total (# colonized/total mice) 
Type of 
Infection
NTBF / ETBF Co-Colonization
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Supplemental Figure 6: B. fragilis strain-specific immunofluorescence. Optimization of 
IF staining was done on formalin-fixed B. fragilis NTBF and ETBF culture pellets. Image 
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Supplemental Figure 7: Periodic acid-Schiff (PAS) stains matched to IF images. PAS 
stains for carbohydrate macromolecules, showing the level of mucus preservation 
retained in presented images. A. PAS images parallel to Fig. 3A B. PAS images parallel 


































Figure 5. Therapeutic treatment with NTBF fails to disrupt ETBF strain dominance 
and disease burden. A-D SPF WT mice were stably infected with ETBF or NTBF for 2 
weeks and then treated with NTBF or ETBF, respectively (ETBFàNTBFR and 
NTBFàETBFR). Superscript R denotes repeated treatments for 9 days. Mice were rested 
for 2 days before sacrifice. Symbols represent individual mice. Data shown include a 
single experiment with 4 to 5 mice per treatment group. Bars indicate median and 
interquartile range. A Strain quantification as measured by stool qPCR at sacrifice. 
Circles represent individual mice. Red: 3 of 5 ETBFàNTBFR mice establish detectable 
levels (102  - 106 copies) of treatment strain NTBF (mouse ID: 62, 61, 59). Purple: 0 of 5 
NTBFàETBFR mice exhibit detectable levels of challenge strain ETBF. B 
Representative images of cecum and spleen: ETBFàPBSR control and ETBFàNTBFR 
ceca are small, pale, and contracted; spleens are enlarged. NTBFàPBSR control and 
NTBFàETBFR ceca are comparable to ShamàPBSR mice (not shown) in size, brown 
color, and content; spleens are not enlarged. C Mouse cecum weights normalized to total 
body weight. ETBFàNTBFR cecum weights are comparable to ETBFàPBSR controls, 
indicative of disease. NTBFàETBFR cecum weights are significantly higher when 
compared to ETBFàPBSR control and ETBFàNTBFR mice, indicative of protection. D 
Mouse spleen weights normalized to total body weight. ETBFàNTBFR spleen weights 
are significantly higher when compared to NTBFàETBFR mice but comparable to 
ETBFàPBSR controls, indicative of disease. NTBFàETBFR spleen weights are 





Figure 5: Therapeutic treatment with NTBF fails to disrupt 




























































































































































Figure 6. PSA-competent and PSA-deficient NTBF do not alter IL-17A+ T cell or 
Treg responses in SPF mice. LPLs were isolated from distal colons of SPF WT and SPF 
Min mice 2 weeks after Sham, NTBF, or ΔPSA NTBF treatment. LPLs were subjected to 
4 hour incubation with cell stimulation cocktail and subsequent ICS for IL-17A and 
Foxp3. Data are presented as percent IL-17A+ of live CD3+ lymphocytes and percent 
Foxp3+ of live CD3+ CD4+ lymphocytes (top). Live CD3+ IL-17A+ and live CD3+ CD4+ 
Foxp3+ cell numbers were also normalized by the mass of colon tissue (bottom). Symbols 
represent individual mice. Bars indicate mean +1 SD. Data shown include two separate 
experiments with 4 to 5 mice per treatment group. No significant differences were noted 
among WT and ΔPSA NTBF treatment groups in any parameters tested in SPF WT or 










Figure 6: PSA-competent and PSA-deficient NTBF d not alter 











































































































Supplemental Figure 8: IFNγ+ and IL-17A+ Foxp3+ T cell responses in the colon LP of 
SPF WT and Min mice colonized with NTBF or ΔPSA NTBF. Individual colons were 
harvested from WT and Min mice of 2 replicate experiments, 4 or 5 mice per group 
(shown in Fig. 6). Data are presented as percentage, IFNγ+ of live CD3+ lymphocytes and 
Foxp3+ of live CD3+ IL-17A+ lymphocytes (top), and as T cell density (# of cells per 






























































































































Supplemental Figure 9: T cell response in the MLNs and spleens of SPF mice colonized 
with NTBF or ΔPSA NTBF. MLNs and spleens were pooled from WT (closed circles) 
and Min (open circles) mice of 2 replicate experiments (shown in Fig. 6), 4 or 5 mice 
pooled per experiment. Data are presented as percentage (top row) and T cell density (# 
of cells per gram of colon tissue) (bottom row). No differences between sham, NTBF, or 
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Supplemental Figure 10: Splenic morphology of SPF and GF monocolonized mice. A. 
Representative H&E stains of formalin-fixed spleens of SPF and GF sham and 
monocolonized mice 8wk post-infection. B. After formalin-fixation, spleens from GF 
mice were weighed. SPF C57BL/6 control mouse spleen weights consistently range from 
0.05g-0.1g. All spleens from monocolonized GF mice (2 to 8wk p.i.) fell within this 
normal range with no differences seen among treatment groups. Bars indicate median and 













































Figure 7. PSA-competent NTBF does not alter Th17, Treg, or Th1 responses in GF 
mice. A LPLs were isolated from distal colons of GF WT mice 2 and 8 weeks after 
Sham, NTBF, or ΔPSA NTBF treatment. Data represent absolute cell number normalized 
to colon tissue mass. Symbols represent individual mice. Bars indicate mean +1 SD. Data 
shown include two separate experiments with 4 to 5 mice per treatment group. Only total 
IFNγ results differed between NTBF and ΔPSA NTBF mice. B In parallel, GF mouse 
distal colon tissue was harvested for whole tissue qRT-PCR. No differences were 
observed among treatment groups in total IL10, IFNG, and IL4 expression, although 
monocolonized mice exhibited increased IL17A expression compared with uninfected GF 
controls at 2 weeks but not at 8 weeks. Bars indicate median and interquartile range. Data 





Figure 7A: PSA-competent NTBF does not alter TH17, Treg,








































































Figure 7B: PSA-competent NTBF does not alter TH17, 
























































































































Supplemental Figure 11: IL-17A+ and IFNγ+ γδ T cell responses in the colon lamina 
propria of GF mice colonized with NTBF or ΔPSA NTBF. Individual distal colons were 
harvested from GF mice of 2 replicate experiments, 4 or 5 mice per group (shown in Fig. 
7). Data are presented as T cell density (# of cells per gram of colon tissue) 2 weeks (top) 


















































Figure 8. ETBF secretes an intraspecies inhibitory molecule. A Overlay of individual 
NTBF and ETBF growth curves. There are no growth differences observed between 
strains. Curves represent the average of the triplicate values. B Co-inoculation assay of 
NTBF with ETBF. Isolated B. fragilis colonies (10) plated from co-cultures were 
randomly selected and screened by strain-specific PCR. After equal parts inoculation, 
NTBF is no longer detected at 24 and 48 hours. C Co-inoculation assay of NTBF with 
ETBF. After differential inoculation, NTBF is only detected at an input ratio of 90:10 
(NTBF:ETBF) at 24 and 48 hours. D Agar diffusion assay of NTBF indicator strain 
(grown on the agar) with ETBF cell-free supernatant (in wells). A zone of clearing 
(stippled line) is induced by the ETBF stationary phase supernatant. Protease treatment 
with trypsin and proteinase-K and heat treatment at 100oC destroys ETBF supernatant 
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Supplemental Figure 12: ETBF secretes an intraspecies inhibitory molecule, active on 
ΔPSA NTBF, K570 ETBF (BFT-3 isolate), and VPI ETBF (BFT-1 isolate). Agar 
diffusion assay of various B. fragilis indicator strains plated on the agar with ETBF WT 



































Supplemental Figure 13: B. fragilis BSAP-1 and ccf gene expression. A. RNA was 
extracted from stationary phase cultures of NTBF and ETBF. cDNA was synthesized and 
SYBR Green PCR was run with BSAP-1 (primer set 3) and B. fragilis 16S (primer set 8) 
primers (Supp. Table 1). Raw Ct values are presented. B. Distal colon whole tissue RNA 
was extracted from SPF Sham, NTBF, or ETBF colonized mice (same mice presented in 
Figure 1). cDNA was synthesized and ccfA (sigma factor) and ccfB (anti-sigma factor) 
gene expression was determined via SYBR Green PCR with primer sets 4 and 5 (Supp. 
Table 1). Samples were normalized to B. fragilis 16S and presented as fold expression 






















































































































CHAPTER 3 - IL-22 in enterotoxigenic B. fragilis disease 
 
Background 
In an effort to understand the molecular mechanisms underlying CRC 
development, gut immune signaling pathways are currently being studied. For instance, 
signaling by interleukin-22 (IL-22), a potent cytokine effector molecule and STAT-3 
activator, is under intense investigation. Clinically, in patients with sporadic CRC, IL-22-
producing cells and IL22 gene expression levels were enriched in the tumor versus 
normal mucosa or paratumor sites161,162. Similarly, IL-22 was found to be more highly 
expressed in tumor-infiltrating leukocytes (TILs) isolated from fresh colon tumors versus 
the peripheral blood or normal controls. IL-22-related proteins IL-23, IL-22RA1, and the 
phosphorylated active form of STAT-3 (pSTAT-3) were overexpressed in colon cancer 
tissues, appearing to localize in tumor and intestinal epithelial cells as measured and 
detected by IHC163. Co-transplantation of patient IL-22-expressing TILs or IL-22 
directly, along with a colon cancer cell line, induced tumor growth and metastasis in 
subcutaneous transplantation mouse models162,163. Notably, Andoh et al., Jiang et al., and 
others showed that individuals with active IBD maintained increased levels of IL-22 
expression in their inflamed colonic mucosa163–165. Additional microarray and functional 
analyses with human sub-epithelial myofibroblasts (SEMFs) showed an IL-22-induced 
upregulation of inflammatory cytokines (IL-6, IL-8, IL-11, LIF) and matrix-degrading 
molecules (MMP-1, MMP-3), alluding to the possible role of IL-22 in IBD inflammation 
and tissue remodeling164. Furthermore, a commonly inherited IL-22 genetic 
polymorphism, the rs1179251 G variant, has been positively associated with colon cancer 
with haplotype analysis suggesting a 52% increased risk for those carrying at least one 
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copy166. Collectively, examples from both the IBD and CRC literature suggest that IL-22 
may be a critical component in intestinal inflammation and the transition from colitis to 
cancer. 
A member of the IL-10 cytokine family, IL-22 is known to be expressed by CD4+ 
T cells of the TH0, TH17, and TH22 subsets, as well as by some members of the more 
recently described ROR-γt+ innate lymphoid cell (ILC) family, including Nkp46+ NK-22 
cells, CD4+ LTi cells, and colonic ILCs161,167. IL-22 interacts with a heterodimeric 
receptor, comprised of IL-10R2 (shared by IL-10) and IL-22RA1 (specific to IL-22)167. 
As IL-10R is expressed ubiquitously, IL-22RA1 is the likely determining factor of the 
cellular targets of IL-22 and is typically found expressed on non-hematopoietic tissue, 
including the epithelial cells and SEMFs of the small and large intestines167. As such, in 
the context of the colon, reports indicate that IL-22 signaling is critical to the 
maintenance of epithelial cell innate immunity, protection, and repair. As very little is 
known about the role of IL-22 in microbial-induced colitis and CRC, we aimed to study 
IL-22 in mouse models of ETBF infection. 
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Materials and Methods 
 
ETBF Mouse Models 
C57BL/6 IL-22-/- mice were obtained from Genentech and crossed into the 
C57BL/6 MinApc716+/- background. WT (non-Min) IL-22-/- mice were used for colitis 
experiments and Min IL-22-/- mice were used for tumor experiments. In the main text, 
Min = MinApc716+/- and IL-22KO = IL-22-/- mice. Mice were housed in specific pathogen 
free conditions according to the Association for the Assessment and Accreditation of 
Laboratory Animal Care International. All protocols were approved by the Johns Hopkins 
University Animal Care and Use Committee. Three to four-week old mice were placed 
on antibiotic water containing clindamycin (0.1 g/L) and streptomycin (5 g/L) for 5 to 7 
days prior to infection. Enterotoxigenic B. fragilis strain 86-5443-2-2 was used for all 
mouse experiments74,75. Bacteria were grown anaerobically at 37oC with brain-heart 
infusion (37 g/L) (BD Bacto) culture media supplemented with yeast extract (5 g/L) (BD 
Bacto), L-cysteine (50 mg/L) (Sigma), hemin (0.5 mg/L) (Sigma), vitamin K (0.1 mg/L) 
(Sigma), and clindamycin (10 µg/ml) (Research Products International). In preparation 
for orogastric administration, bacterial pellets were washed twice and suspended with 
sterile 1X Dulbecco’s phosphate-buffered saline (1X PBS free of calcium chloride & 
magnesium chloride). All mice received 100 µl of the inoculum, corresponding to ~108 
ETBF CFU per mouse. The 86-5443-2-2 strain is innately resistant to both clindamycin 




Intestinal Permeability  
 Intestinal permeability was analyzed by a method adapted from Wang et al.168. 
Four hours prior to sacrifice, food was removed and mice received an orogastric 
administration (20 ml/kg body weight) of a 22 mg/ml fluorescein isothiocyanate-dextran 
stock (FITC-dextran, avg. molecular weight 4,000) (Sigma 46944). At sacrifice, blood 
was harvested by cardiac puncture and allowed to clot at room temperature. Blood 
samples were centrifuged at 3,000 rpm for 20 minutes at 4oC, and serum was harvested. 
Serum samples were diluted 1:2 with sterile 1X PBS (pH 7.4) and aliquoted to a clear-
bottom, black 96-well plate (Corning 3603) in triplicate wells. Fluorescein concentrations 
were determined by spectrofluorometric plate reader (excitation 485 nm and emission 
530 nm), using serially diluted samples of the FITC-dextran marker as the standard. 
 
Immunohistochemistry 
 pSTAT-3 and BrdU staining was done in accordance with standard 
immunohistochemistry protocols. FFPE tissues were deparaffinized, rehydrated, and 
subjected to antigen retrieval by steaming with citrate buffer (1.8 mM citric acid and 8.2 
mM sodium citrate) for 30 minutes. Endogenous peroxidase was quenched by treatment 
with 3% H2O2 for 10 minutes. After blocking, tissue sections were incubated with either 
rabbit anti-pSTAT3 primary or biotin-conjugated anti-BrdU primary overnight at 4oC 
followed by the secondary antibodies Powervision Poly-HRP anti-rabbit (Leica PV6119) 
or streptavidin-HRP, respectively, for 1 hour at RT. DAB development was done for 20 
minutes. Tissues were counterstained with hematoxylin. 
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Statistical Analysis           
 Unless otherwise indicated, the nonparametric two-tailed Mann-Whitney U test 
was used to compare means of all treatment groups. A p value of <0.05 was considered 
significant. 
 
Fecal Colonization and Mucosal Adherence 
Assays were carried out according to previously described methods (Ch. 2, pg. 27).   
 
Quantitative RT-PCR 
Assays were carried out according to previously described methods (Ch. 2, pg. 27-28). 
 
Histology, Microadenoma, and Macroadenoma Counts 
Assays were carried out according to previously described methods (Ch. 2, pg. 28). 
 
LPL Isolations 
Assays were carried out according to previously described methods (Ch. 2, pg. 30). 
 
Flow Cytometry and FACS 
Assays were carried out according to previously described methods (Ch. 2, pg. 30). In 










IL-22 Protects Against Epithelial Cell Shedding and Intestinal Permeability 
In the absence of IL-22, we sought to evaluate the impact on ETBF colitis. 
C57BL/6 WT and IL-22KO mice were infected with ETBF and analyzed at day 1, day 3, 
and day 7 post-infection. Fecal and mucosal ETBF colonization was similar between IL-
22KO mice and parental controls (Supp. Fig. 1). During the acute stage of infection, IL-
22KO mice exhibited striking colon epithelial cell shedding (anoikis), indicative of 
cellular apoptosis (Fig. 1A). At 3 days, IL-22KO mice displayed the highest anoikis 
disease scores in comparison with WT mice (p=0.009) (Fig. 1B). Suspecting that these 
marked tissue disruptions may impact barrier function, we analyzed intestinal 
permeability by means of fluorescein isothiocyanate (FITC) detection in the blood. In 
mice receiving FITC-dextran by oral gavage, we discovered that ETBF-infected IL-
22KO mice displayed the highest concentrations of FITC in the serum compared to WT 
controls (p=0.003), coinciding with the time point at which severe epithelial cell shedding 
occurred (Fig. 1C). Other characteristic histopathological features of ETBF colitis, 
hyperplasia and inflammation, were comparable between WT controls and IL-22-
deficient mice (Fig. 1D). Both treatment groups displayed a synchronous increase in 
these histopathologic parameters over the course of the infection. As IL-22 has a 
purported role in wound healing and tissue repair, we sought to evaluate proliferation in 
IL-22KO mice. Twenty-four hours prior to terminal sacrifice, mice were given 
bromodeoxyuridine (BrdU) by intraperitoneal injection; mice colonized with ETBF for 3 
days were assessed. Epithelial cell proliferation in mouse colons was evaluated by 
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immunohistochemistry. Stained slides were observed for the number of BrdU-positive 
cells and the migration distance of BrdU-positive cells along the crypt-villus axis. No 
differences were observed in this proliferative marker between groups (Supp. Fig. 2). 
These data point towards the vital role of interleukin-22 in colon epithelium protection 
and intestinal barrier maintenance. 
 
IL-22 Deficiency Initiates a Pro-Inflammatory Microenvironment   
For all nine select inflammatory and anti-microbial genes analyzed, baseline 
differences between un-infected WT parental and IL-22KO mice were not observed 
(Supp. Fig. 3). Our data show that IL-22 is indeed an important innate immune cytokine, 
with brisk upregulation in IL22 expression seen only one day after ETBF exposure in WT 
mice (Fig. 2A). As described above, the early damage sustained by the epithelium in the 
absence of IL-22 may promote increased mucosal exposure to luminal contents. We 
hypothesized that a transient or persistent interaction of this nature could initiate a more 
severe inflammatory response. Consistent with this hypothesis, we observed that ETBF-
infected IL-22KO mice had increased expression levels of the genes encoding the pro-
inflammatory cytokines IL-11 (day 3 and day 7) (p=0.03 and p=0.02, respectively) and 
IL-17A (day 7) (p=0.01), as determine by whole tissue qRT-PCR (Fig. 2B and D). After 
ETBF colonization, IL-22KO mice appeared to express normal levels of the antimicrobial 
genes, RegIIIβ and RegIIIγ, and the nitric oxide synthase gene, NOS2 (Supp. Fig. 4) 
Furthermore, although IL-22 is a potent STAT-3 activator, IL-22KO ETBF-colonized 
mice continue to exhibit potent STAT-3 activation as measured by immunohistochemical 
staining (Fig. 2C). In both WT and IL-22-deficient mice, pSTAT-3 was detected in both 
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the colon epithelial cell and lamina propria compartments. This finding is demonstrative 
of the host’s redundant mechanisms that contribute to STAT-3 signal transduction. For 
instance, ETBF-colonized mice deficient in IL-6, another known STAT-3 activator, also 
exhibited sufficient pSTAT-3 staining (Supp. Fig. 5). In our model, the notable increase 
of IL11 expression, an IL-6 cytokine family member, may be compensatory in response 
to ETBF infection.  
 
IL-22 Deficiency Promotes Adenoma Formation  
Although IL-17 acts as a potent anti-microbial component of host defense, IL-17 
has also been shown to be pro-tumorigenic169. Thus, we next evaluated the impact of IL-
22 deficiency on microadenoma and macroadenoma development in Min IL-22KO mice. 
Fecal ETBF colonization was comparable between Min IL-22KO mice and Min parental 
controls (Supp. Fig. 1). Overall, only a modest, non-significant increase in 
microadenoma formation was observed 2 to 3 weeks after ETBF colonization of Min IL-
22KO mice compared to ETBF-colonized parental Min mice (Fig. 3A). Yet, intriguingly, 
ETBF-colonized Min IL-22KO mice developed significantly more macroscopic tumors 
compared with ETBF-colonized parental Min mice from 1 to 3 months post-infection 
(overall p-value=0.0001) (Fig. 3B-C). Together, these data strongly suggest that the brisk 
IL-22 response to ETBF infection (Fig. 2A) acts to inhibit tumor development in 
response to ETBF infection.  
Early (1 week) evaluation of distal colon tissue by qPCR from ETBF-colonized 
Min IL-22KO mice and matched Min parental controls showed that IL-17A and IL-11 
inflammatory responses were specifically induced by the B. fragilis toxin, BFT; 
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colonization with an ETBF bft-mutant (Δbft-2) yielded gene expression levels 
comparable to sham mice (Supp. Fig. 6). Although IL11 expression levels were similar 
between ETBF-colonized Min IL-22KO mice and Min controls, IL17A expression was 
significantly higher in the Min IL-22KO treatment group (Supp. Fig. 6). To evaluate 
possible differences within the tumor microenvironment in the presence or absence of IL-
22, tumors were harvested from Min parental and Min IL-22KO mice to analyze gene 
expression through qPCR. However, no differences were observed in total tumor 
expression of IL17A, potent STAT-3 activators IL6 and IL11, and nitric oxide synthase 
encoded by the NOS2 gene (Supp. Fig. 7). 
 
IL-22 Deficiency Promotes a Specific Myeloid Expansion 
 Flow analysis of lamina propria isolates from parental Min and Min IL-22KO 
mice colonized with ETBF for 1 week showed an expansion of myeloid subsets 
characterized by low MHC Class II expression (MAC2) (Fig. 4). Additionally, we 
observed a trend for the expansion in Min IL-22KO mice of what we are defining as 
‘MAC1’ cells, characterized by MHC Class II high expression. The myeloid cells of 
interest were gated as CD45+/CD11b+, Ly6C-/Ly6G-, and MHC Class II high or low. 
Concurrently, the number of CD103+ dendritic cells was significantly lower in the Min 
IL-22KO deficient mice. The number of polymorphonuclear (PMN) cells remained 
similar between both parental Min and Min IL-22KO mice (Fig. 4). The literature has 
defined two polarized macrophage types: 1) classically activated (M1) induced by GM-
CSF, TNFα, and IFNγ alone or together with LPS and 2) alternatively activated (M2) 
induced by IL-4 and IL-13. M1 macrophages are typically viewed as pro-inflammatory 
	 87	
with high production of IL-1, TNFα, and IL-6 along with nitric oxide and reactive 
oxygen species and high antigen presentation capacity, whereas M2 macrophages are 
typically viewed as anti-inflammatory, with high production of IL-10 and involvement in 
homeostasis and cellular repair170. Until the function and phenotype of the ‘MAC1’ and 
‘MAC2’ cellular populations from our mice can be established, no similarities can be 
drawn with the M1/M2 macrophage paradigm. We have sorted these cells for 
transcriptional analysis.  
 
Discussion and Future Steps 
 
 Reports indicate that IL-22 can have dual roles, dependent on model and context, 
acting in ways that can be either protective or harmful to the host. In experimental 
models, multiple studies have shown that IL-22 acts as a host-protective cytokine in the 
gut, promoting preservation of the mucosal barrier through goblet cell maintenance and 
mucin production, production of antimicrobial peptides and chemokines, and epithelial 
cell regeneration171. For instance, directed, localized microinjections of IL-22 into the 
colons of mice protected them from a Th2-induced form of colitis through the ability to 
retain goblet cells and induce mucus production172. Additionally, IL-22 protected mice 
from colitis induced by murine pathogen, Citrobacter rodentium, likely through induction 
of regenerating islet-derived protein 3 (RegIIIβ and RegIIIγ) antimicrobial production173; 
a microbe related to human attaching and effacing pathogens, e.g. enterohemorrhagic 
(EHEC) and enteropathogenic (EPEC) E. coli, C. rodentium intimately attaches to and 
causes effacement of host intestinal epithelial cells. In contrast, IL-22 has a documented 
capacity to induce intestinal pathology in a cell-transfer colitis model. In this model, mice 
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that received cell transfer from IL-22KO mice had reduced disease severity with 
diminished body mass loss, reduced colitis, and increased colon length174. Additionally, 
IL-22 production by ILCs has been shown to be a driver of invasive colon cancer in Rag-
deficient mice infected with Helicobacter hepaticus and treated with azoxymethane 
(AOM)161. Further, the direct action of IL-22 to activate STAT-3, a signaling molecule 
implicated in numerous colitis-associated-cancer animal models and in CRC itself, 
portrays IL-22 as a promoter of aberrant cellular growth, detrimental to the host. Further 
in vitro studies by Ziesche et al. are consistent with these data, showing that IL-22 
together with IFNγ can induce the production of reactive oxygen species (e.g. iNOS) 
typically associated with cancer, in human colon carcinoma cell lines175.  
In our ETBF model of colitis and colon tumorigenesis, it appears that IL-22 plays 
a protective role, likely combating pathogenic ETBF in its early stages of infection and 
contributing to epithelial barrier maintenance. In contrast to previous studies, we did not 
observe any early deficiencies in antimicrobial peptide or nitric oxide synthase gene 
expression in WT (non-Min) IL-22-deficient mice infected with ETBF (Supp. Fig. 4), 
nor did we observe any loss of STAT-3 activation (Fig. 2C) (Supp. Fig. 5). Competent 
STAT-3 activation was also observed in ETBF-infected IL-6-deficient mice (Supp. Fig. 
5) suggesting that many redundancies exist in this crucial signal transduction pathway in 
the ETBF model. We hypothesize that increased damage to the epithelium in the absence 
of IL-22 promotes increased activation of the mucosal immune system, resulting in 
increased IL-17 and IL-11 responses that contribute to tumor initiation. In spite of the 
increased intestinal permeability and inflammatory burden observed in IL-22-deficient 
mice, the level of ETBF fecal and mucosal colonization remained similar between IL-22 
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KO mice and parental controls (Supp. Fig. 1). Furthermore, un-defined MHC class IIlow 
macrophage subtypes also accrue in the lamina propria of ETBF-colonized Min IL-22-
deficient mice that may be pro-carcinogenic. We would like to understand the phenotype 
and function of these novel myeloid cell populations as well as the role of IL-22 in the 
regulation of these macrophage populations; it is suspected that mediation is through 
colon epithelial cells expressing IL-22RA1, possibly through control of chemokine or 
barrier function effectors. 
 Questions remain regarding the specific mechanism underlying increased 
adenoma development in the absence of IL-22. For instance, in the M1/M2 paradigm, 
M1-like macrophages are thought to be anti-tumorigenic due to their cytotoxic 
capabilities and improved antigen presentation leading to better immune surveillance, 
whereas M2-like macrophages are thought to promote tumors due to their 
immunosuppressive nature and pro-angiogenicity. Some studies have shown that the re-
education of tumor microenvironment (TME) M2-like macrophages into M1-like 
macrophages leads to improved anti-tumor immunity and tumor growth reduction176. One 
hypothesis is that IL-22 deficiency promotes the accumulation of specific macrophage 
populations whose primary function entails epithelial tissue remodeling and repair (M2-
like); the presence of such cells could promote an increase in aberrant cellular growth. To 
address this hypothesis, myeloid-derived ‘MAC1’ and ‘MAC2’ cell subsets have been 
sorted from one week ETBF-infected Min IL-22KO and parental Min control mice. To 
characterize the phenotype and function of these populations, these cells will be analyzed 
for mRNA expression of key genes of interest: pro-inflammatory cytokines, chemokines, 
reactive oxygen species, and cell proliferative markers, using high-throughput qRT-PCR 
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array plates. Furthermore, it will be exciting to uncover any links existing between IL-
11/IL-17 expression and recruitment of these macrophage subsets. Understanding the 
interplay between the enhanced epithelial cell shedding (Fig.1A & B) and permeability 
(Fig. 1C) with macrophage recruitment will also be crucial. In response to cell damage 
and altered intestinal barrier function, are specific macrophages called to repair the 
damage, and in the case of ETBF, is this a case of a good response gone bad? 
 To further probe this hypothesis of ‘pathogenic’ or tumor-promoting 
macrophages in ETBF disease, murine macrophage depletion experiments will also be 
conducted. Previous attempts at colonic macrophage depletion by administering 
commercially available chlodronate-containing liposomes were unsuccessful. CD11b-
DTR mice (official designation: FVB-Tg(ITGAM-DTR/EGFP)34Lan/J) were recently 
obtained from Jackson Laboratories and crossed into the Min background. Future studies 
will utilize diphtheria toxin-mediated depletion of macrophages during ETBF infection, 






Main and Supplemental Figures/Tables (in order of first reference) 
 
Supplemental Figure 1: IL-22 deficiency does not modify ETBF colonization. 
After being placed on antibiotic water, ad libitum, for 5 to 7 days, WT and IL-22KO mice 
and parallel Min mice received orogastric treatment with ETBF. A At respective time 
points, feces were collected, homogenized, and cultured for determination of B. fragilis 
colony-forming units (CFU) per gram of stool. Colonization was similar between WT 
and IL-22KO mice. B At sacrifice, ranging from 7 to 28 days p.i., colon tissue from WT 
and IL-22KO mice was pulverized and cultured to quantify tightly adherent ETBF (CFU 
per gram of tissue). Aggregate data is presented. ETBF mucosal adherence was 

















WT     B6


































Figure 1: IL-22-deficient mice exhibit severe epithelial cell damage and intestinal 
permeability. WT and IL-22KO C57BL/6 mice were inoculated with ETBF and 
sacrificed 1, 3, and 7 days afterwards. H&E-stained FFPE colon tissues were analyzed for 
histopathology. Bars = Mean + SEM. Data are from 2 replicate experiments. A 
Representative histopathology, displaying severe epithelial cell shedding (anoikis) in IL-
22KO mice versus WT controls. Red arrow depicts characteristic cell rounding and 
detachment, indicative of apoptosis. B Disease scores of colon anoikis. At an early time- 
point (day 3), IL-22KO mice exhibit a more severe anoikis score than WT controls. C 
Intestinal permeability as measured by FITC-dextran concentrations in the serum. ETBF-
infected IL-22KO mice exhibit increased intestinal permeability at day 3 p.i. D Disease 
scores of colon hyperplasia and inflammation are comparable between WT and IL-22KO 
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Supplemental Figure 2: Epithelial cell proliferation is comparable between WT and 
IL-22-deficient mice. Mice received bromodeoxyuridine (BrdU) by intraperitoneal 
injection 24 hours prior to sacrifice (3 days after ETBF inoculation). The number of 
BrdU-positive cells and migration distance along the crypt-villus axis are comparable 















Supplemental Figure 3: Baseline gene expression in un-infected WT and IL-22-
deficient mice. Normalized Ct values were compared between Sham (PBS-treated) WT 




































































































































Figure 2: Early cytokine expression in IL-22-deficient mice. ETBF-inoculated WT 
and IL-22KO C57BL/6 mice, analyzed at days 1, 3, and 7 p.i.. Distal colon tissue (2nd cm 
piece in from the most distal colon region) was harvested for whole tissue qRT-PCR. 
Data are presented as fold expression over sham. Bars = Mean + SEM. Data are from 2 
replicate experiments. A In WT mice, IL22 is most highly expressed immediately after 
infection. IL22 expression was not detected (ND) in any IL-22-deficient mice.  B IL11 
continues to be expressed more highly in IL-22KO mice at days 3 and 7 p.i.. C pSTAT-3 
IHC staining shows comparable STAT-3 activation between IL-22KO mice and WT 
controls in both epithelial and lamina propria compartments. D IL17A expression 
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Supplemental Figure 4: Additional gene expression analysis of WT and IL-22-
deficient mice. Baseline RegIIIβ, RegIIIγ, and NOS2 expression was analyzed in ETBF-
colonized WT and IL-22KO mice. Bars = Mean. Expression of these genes was 






























































































Supplemental Figure 5: pSTAT-3 detection is comparable among control, IL-6-
deficient, and IL-22-deficient mice. ETBF-colonized mice were sacrificed at 1 week 
(WT mice) and 12 weeks (Min mice). FFPE tissue sections were stained for pSTAT-3 
and representative images were taken with 10X objective lens. pSTAT-3 detection was 



















Figure 3: IL-22-deficient mice exhibit a higher adenoma burden. Adenomas were 
quantified in WT and IL-22KO C57BL/6 Min mice after ETBF inoculation. Bars = Mean 
+ SEM. Data are from 2 to 3 replicate experiments. A H&E colon sections displaying 
characteristic microadenoma morphology. Quantification of microadenomas from 
individual mice observed at 2 to 3 weeks p.i.. A significant increase in microadenomas 
was not observed in ETBF-colonized Min IL-22KO mice versus parental Min controls. B 
Images of representative methylene blue-stained distal colons 3 months p.i.. Infected Min 
IL-22KO mice display increased macroadenoma development compared with infected 
Min mice. Tumor counts are recorded for the entire colon. C Quantification of 
macroadenomas from individual mice. Min IL-22KO mice exhibit increases in 
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Supplemental Figure 6: BFT induces the inflammatory response in Min mice. 
Parental Min and Min IL-22KO mice were colonized with either Δbft-2 ETBF mutant or 
parental ETBF bacterial strains and sacrificed 1 week later. Distal colon tissue was 
evaluated for cytokine expression by qPCR. IL17A and IL11 gene expression was 
increased in mice colonized with parental ETBF compared with Δbft-2 ETBF; BFT is 
required for induction of the inflammatory response. ETBF-colonized Min IL-22KO 





































































































Supplemental Figure 7: Gene expression in IL-22-competent or IL-22-deficient 
tumors. Tumors were harvested from ETBF-infected Min parental and Min IL-22KO 
mice and gene expression assessed by qPCR. Data are presented as change in fold 
expression compared to ETBF-infected Min parental mice. Bars = Mean. Tumors from 
ETBF-colonized parental Min and Min IL-22KO mice display similar expression levels 
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Figure 4: Expansion of specific myeloid subsets occurs in IL-22-deficient mice. The 
lamina propria immune cells of C57BL/6 parental Min and Min IL-22KO mice were 
analyzed by flow cytometry 1 week after ETBF inoculation. Data are presented as total 
cell number normalized by colon tissue mass from which the cells were isolated. Bars = 
Mean + SEM. Data are from 2 replicate experiments. red = expt 1; black = expt 2. Live 
cells were gated as CD45+/CD11b+, Ly6C-/Ly6G-, and either MHC Class II high or low. 
Min IL-22KO mice show a trend of increased ‘MAC1’ (Class IIhigh) cell accumulation 
and a significantly increased ‘MAC2’ (Class IIlow) cell accumulation in comparison with 
Min controls. The number of polymorphonuclear (PMN) cells is comparable between 
groups. Min IL-22KO mice show a significant decrease in the number of CD103+ 





































































CHAPTER 4 - Bacterial induction of immune homeostasis: a clinical 
and historical context 
 
The Clinical Picture 
Studying the impact of the gut microbiota on the host immune response, and vice 
versa, has given us more insight into how intestinal homeostasis is established and how 
extensive co-evolution has shaped both systems. Understanding these interactions also 
has immense potential for clinical application. Within the last quarter century in the 
United States, the number of newly discovered or synthesized antibiotics has been 
steadily decreasing. A striking depiction of this can be seen through evaluating the 
number of “systemic antibacterial new molecular entities” approved by the U.S. Food and 
Drug Administration (FDA) in 5-year increments of this time period (Fig. 1)177. For 
instance, from 1983-1987, 16 new antibacterial agents were approved; from 1993-1997, 
10 new agents were approved and from 2008-2012, only a mere 2 new agents had been 
approved. Numerous reasons are cited for the decrease in antibiotic development, mainly 
dependent on lack of financial incentive for drug companies. For one, antibiotics 
typically have less of a return on investment than do other drugs178; this is due to their 
relative success as a treatment, requiring only short-course administration while typically 
curing the disease. This is in contrast to medications used in the treatment and 
management of long-term, chronic conditions, which are typically used for a lifetime. 
Additionally, the general consensus by the scientific community to limit the use of broad-
spectrum antimicrobials coupled with the lack of formal FDA guidelines for the testing of 
new antibiotic agents, further deters their development177. It is clear that antibiotic 
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alternatives should be developed. In the context of intestinal conditions and diseases, one 
avenue of treatment may be through manipulation of the gut microbiome. This could 
come through the form of prebiotics (food sources promoting beneficial organisms), 
probiotics (beneficial live organisms), or synbiotics (combination of pre- and probiotics).   
 
Figure 1: Systemic antibacterial new molecular entities approved by the FDA177  
 
 
 The utility of probiotics or live microorganisms in human intestinal health is 
currently being explored. Intriguingly, Dale Gerding and colleagues recently conducted a 
phase 2 randomized double-blinded, placebo-controlled (RDBPC) trial using the obligate 
anaerobe, nontoxigenic Clostridium difficile (NTCD), to prevent recurrent C. difficile 
infection (CDI) (Fig. 2). A major cause of nosocomial antibiotic-associated diarrhea, 
toxigenic C. difficile is a significant cause of morbidity and mortality in the United States, 
found to have caused ~ 453,000 infections and causing 29,000 deaths in 2011179. As a 
spore-former, resistant to conventional cleaners and alcohol-based hand washes, C. 
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difficile is highly contagious with high rates of recurrent infection. In the study, it was 
found that oral administration of NTCD spores in humans was well-tolerated and safe 
while significantly reducing CDI recurrence180. 
 
Figure 2: Nontoxigenic C. difficile spores as treatment for recurrent CDI180 
 
 
Convergence of Colorectal Cancer Risk Factors 
With notable differences (noted in Chapter 1) in the gut microbiota of CRC 
patients compared with healthy individuals, this may suggest that directed microbiome 
alteration may be beneficial in this disease. Numerous risk factors have been identified in 
CRC development. Most CRC cases are sporadic, meaning non-hereditary (~75%), and 
other cases are hereditary. Risk factors that may initiate and/or promote CRC include age 
(typically >50 years old), physical inactivity, obesity, diet (increased consumption of red 
and processed meats; diminished consumption of fruits, vegetables, and whole grain 
fibers), smoking, heavy alcohol use, and history of IBD (Fig. 3)181. There may also be 
underlying genetic factors affecting the development of certain CRC “environmental” 
risk factors, e.g. obesity/BMI182, diet183, and physical activity/lifestyle184,185. In turn, these 
combined factors, along with host-defined immune responses and gut architecture, impact 
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the microbiome composition of the gut186. Dictating microbial stability and dysbiosis, 
these elements may influence overall disease burden in patients. Furthermore, in CRC, it 
can be imagined that a host of acute triggering events such as antibiotic usage, foodborne 
illness, parasitic infection, etc., may also tip the microbiome balance in one direction or 
the other, influencing the burden and action of potentially oncogenic pathobionts. 
 
Figure 3: Colorectal cancer risk factors  
The interplay of host genetics with numerous factors, including diet, lifestyle, obesity, 
and history with IBD likely all converge to impact an individual’s risk of colorectal 
cancer. Genetics also likely impact the composition of the gut microbiome, influenced by 
single microbes and the consortium of the microbial community. Gut microbiome 
composition/dysbiosis itself may also, in turn, impact diet, lifestyle, and the development 





















Historical model of PSA induction of immune tolerance 
Providing the basis for the development of microbial-based treatments and 
therapies, commensal bacteria have been implicated in the induction of innate and 
adaptive mucosal immunity. Utilizing experiments with germ free mice, commensal gut 
bacteria have been reported to stimulate synthesis of angiogenin-4 (a potent bactericidal 
protein), promote B cell IgA production, intestinal epithelial lymphocyte recruitment, and 
lymphoid structural development, e.g. Peyer’s patches187. Considering the complex 
interplay of risk for CRC and other inflammatory intestinal conditions, such as IBD, the 
use of probiotic microbes has been hypothesized as a means to disrupt disease 
progression or to induce disease mitigation.  
In the example of anaerobic commensal bacterium, Bacteoides fragilis, covered 
extensively in chapter 2, NTBF has been reported to induce mucosal immune tolerance 
and to even reduce inflammation in various murine colitis models136. One way that the 
host immune response may contribute to IBD is through secreted inflammatory mediators 
by pathogenic Th17 cells, likely promoting ongoing mucosal inflammation in patients188 . 
A culmination of studies since the early 2000s have been integrated into a model 
hypothesizing the ability of NTBF to disrupt the accumulation of pathogenic Th17 cells. 
This model poses that NTBF PSA, provided through outer membrane vesicles (OMVs), 
is taken up by dendritic cells (DCs) in a TLR-2 dependent manner. Further DC Gadd45a 
signaling and IL-10 production initiates responses from Tregs that may suppress 
pathogenic T cell responses, likely through IL-10 (Fig. 4). Shen et al. recently 
demonstrated that PSA OMVs administered orally or rectally could prevent experimental 
colitis in mice145. 
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Figure 4: Polysaccharide A (PSA) is reported to promote tolerance and suppress 




In summary, the previous literature reported several key findings that our study 
also addressed. First, it was reported that DPSA NTBF exhibited a deficiency in the 
mucosal colonization of GF mice compared with mice colonized with WT NTBF (Fig. 4 
#1)130. Second, researchers reported that colonization of GF mice with DPSA NTBF 
induced a robust expansion of inflammatory Th17 cells, an outcome that was reversed 
when mice were colonized with WT NTBF or DPSA NTBF-colonized mice were treated 
with purified PSA (Fig. 4 #2)130. Third, the colonization of GF mice with WT NTBF or 
treated with purified PSA induced a significant expansion of IL-10 producing regulatory 
T cells (Fig. 4 #3)129. Fourth, it was reported that B. fragilis colonization resistance was 
absolute. For example, it was reported that if one NTBF strain had already colonized a 
Polysaccharide A (PSA) is reported to promote 

















GF mouse, a secondary labeled challenge NTBF strain was unable to establish138. 
However, in our experiments, we demonstrated no difference in mucosal colonization 
between WT and DPSA NTBF in both SPF and GF mice. We did not observe an 
expansion in Th17 cells in the absence of PSA, nor did we observe an accumulation of 
Tregs in the presence of PSA. However, there were some points of overlap with previous 
studies. We found that NTBF could protect from experimental colitis induced by ETBF. 
We also found that although B. fragilis species colonization resistance was quite robust, 
nonetheless, the phenotype was more partial than previously reported (Fig. 5).  
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Microbiome-Host Interactions and Shifting Paradigms 
 The complex crosstalk between microbe and host is an important factor in 
determining the overall mucosal immune response. Historically, researchers have focused 
their efforts on identifying microbial species that have the ability to promote human 
health, i.e. emphasis placed on the effects of microbe-to-host. Although this type of focus 
has been incredibly instructive, this may only partially describe the complex nature of the 
microbiome. In contrast to the conventional view of microbe-to-host directed 
interactions, the surprising findings presented here, describing a conditional NTBF-
mediated protection from ETBF pathogenesis independent of enhanced NTBF-induced 
immunosuppression (Chapter 2), suggest that more emphasis should be placed on 
understanding specific host-to-microbe or microbe-to-microbe directed interactions, i.e. 
emphasis placed on the evolutionary and ecological hurdles that microbes encounter190. 
These challenges could include selective factors coming from the host side, e.g. the 
immune system; it could also include the competition encountered with other microbes in 
the environment. Recent inferences made from applying evolutionary theory to 
mammalian microbiome data suggest that the microbiome may evolve as ‘an ecosystem 
on a leash’190. In other words, while evolution of the microbiota is driven by the need to 
compete and persist within the host, the living host, itself, is under its own natural 
selective pressures to shape a beneficial microbiome (Fig. 6). Thus, the microbiome is a 








Figure 6: Ecosystem on a leash190  
When a host encounters diverse and beneficial microbes, evolutionary theory predicts 
that microbiome evolution is driven by persistence in the host, while the host attempts to 
control the microbiota. black arrows = interactions within the microbiota; red arrows = 
mechanisms of control. 
 
 
Consistent with this proposed model of microbiome development, our data seem 
to also prioritize the importance of microbe-to-microbe interactions in determining 
disease outcome. The ability of NTBF to interact with and establish on the colonic 
mucosa predisposed mice to protection from ETBF (NTBFàETBF mice), likely due to 
the NTBF occupation of the B. fragilis ecological niche (colonization resistance). Yet, 
timing and competition interactions were also important as ETBF dominated the infection 
and disease trajectory in NTBF+ETBF mice.  
In the broader context of microbiome harnessing as a potential treatment, it may 
be more advantageous to understand how microbes compete with one another through 
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metabolism, adhesion, or inhibitory compounds, than to focus solely on how symbionts 
directly affect us190. What would be the purpose of harnessing beneficial microbes if they 
cannot be integrated into the host? And can probiotics really work as one size fits all? 
Further understanding of what makes a stable microbiome susceptible to invasion would 
also be key. Additionally, even without direct impact on the host, there may be symbionts 
that lend benefit to the entire microbial community; it would be helpful to understand 
these interactions. On the one hand, the study of specific microbes in isolation, for 
instance in germ free animals, is essential to creating a simplified system from which 
molecular mechanisms can be identified. On the other hand, the results of isolation 
studies may not represent the overall nuanced outcome in a complex mammalian host. I 
propose that we begin to study the beneficial microbiome through both arms, in isolation 













CHAPTER 5 - Concluding Remarks 
 
Results Summary 
 In this work, an in-depth study of the putative probiotic organism, NTBF, was 
undertaken. We showed that prophylactic treatment with NTBF could restrict the colonic 
establishment of pathogenic ETBF; this protection was independent of NTBF-encoded 
polysaccharide A (PSA). The levels of NTBF and ETBF in co-infected mice were 
quantified, and murine disease burden was analyzed. We found that sequentially treated 
mice (NTBFàETBF) exhibited a pronounced reduction in ETBF colonization burden. 
The mice also displayed diminished colonic inflammation and tumor burden compared 
with ETBF-only controls. However, NTBF protection from ETBF was not absolute, as 
the IL17A expression in NTBFàETBF mice remained significantly higher than NTBF-
only controls, demonstrating the limitations of bacterial colonization resistance. Key 
findings of both ETBF dominance during simultaneous treatment (NTBF+ETBF) of mice 
and ETBF secretion of anti-bacterial inhibitory molecules allude to the complexity of gut 
microbial interactions and community development. Understanding these interactions 
better may further gut microbiome manipulation to promote health and wellness in the 
clinic.  
 Furthermore, we demonstrated that IL-22, an immune signaling molecule, plays a 
host-protective role during murine ETBF infection. Functional IL-22 in the mouse 
promoted intestinal barrier function and mucosal epithelium maintenance. IL-22 
signaling also appeared to prevent a severe inflammatory response, characterized by 
diminished levels of IL17A and IL11 gene expression. In the absence of IL-22 (IL-
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22KO), ETBF-colonized mice developed a higher tumor burden compared with WT (IL-
22-competent) controls. The mechanism by which IL-22 prevents adenoma formation is 
yet to be elucidated. We hypothesize that in the absence of IL-22, the accumulation of 
MHC Class II low macrophages drives epithelial cell proliferation, promoting tumor 
development.  
 
The ‘Good Bugs’ and How to Study Them   
 Dating back to 1908, the idea that specific bacterial species or strains in their live 
form could be used to promote health and wellness started to become a burgeoning topic 
of interest. Nobel laureate, Élie Metchnikov, spent the latter years of his career studying 
specific long-lived human populations in Bulgaria that consumed large amounts of yogurt 
containing lactic acid-producing Lactobacillus bacteria191. In the 1930s, Minoru Shirota, 
a Japanese physician, successfully isolated and cultured the eponymous Lactobacillus 
casei strain Shirota, resistant to gastric and bile acids, and in 1935, developed the Yakult 
probiotic drink incorporating this strain that is still widely used today191. Since then, the 
probiotic market has exploded worldwide with $30 billion in annual sales. However, as 
Dr. Eric Pamer puts it, “…there is little solid evidence in humans of their effectiveness in 
enhancing health, promoting longevity, or reducing infections”192. For truly evidence-
based approaches, the next-generation of probiotic organisms will require more rigorous 
study and analysis, culminating in the clinical evaluation of their safety and effectiveness.  
 The study of individual microbes has provided some insight into how commensals 
may promote intestinal health. For instance, one of the most widely studied and used 
probiotic strains, Lactobacillus rhamnosus GG (LGG), is thought to promote intestinal 
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homeostasis through its strong pilus-mediated intestinal adherence capabilities preventing 
pathogenic colonization; further production of immune effectors, anti-apoptotic proteins, 
and antimicrobials by LGG may also play a role193. Other probiotic formulations come as 
multi-species cocktails, such as VSL#3, thought to suppress intestinal inflammation 
through acetate production and tissue reductions in IFNγ, TNFα, and iNOS194. Pioneering 
research conducted by Smith et al. has shed light on the importance of short chain fatty 
acids (SCFAs) (e.g. acetate, butyrate, and propionate), bacterial fermentation products of 
dietary fiber, in gut health195. On a mechanistic level, the authors show that SCFAs have 
direct receptor-mediated interactions with colonic Tregs through GPCR43, inducing Treg 
expansion, Treg suppressive activity, and protection from colitis all likely mediated 
through histone deacetylase inhibition195. Furthermore, butyrate has been implicated in 
protection from CRC development, with one animal study showing that AOM/DSS-
treated mice colonized with butyrate-producing bacteria and fed a high fiber diet 
exhibited diminished colon tumor development196; other studies suggest a role for 
butyrate in colon motility promotion, apoptosis induction, inflammation reduction, and 
inhibition of tumor cell progression197. In addition, obligate anaerobes noted to be in low 
abundance in dysbiotic states have also emerged as possible novel probiotics. For 
instance, Faecalibacterium prausnitzii, a dominant member of the healthy adult intestinal 
microbiota, has distinct low abundances in cases of irritable bowel syndrome (IBS), IBD, 
CRC, and celiac disease198. Preliminary data from in vitro and animal models suggest that 
treatment with F. prausnitzii bacteria or culture supernatants can diminish colitis through 
butyrate production and secretion of anti-inflammatory metabolites198. In another 
example, Buffie et al. showed through sequencing and mathematical modeling that the 
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presence of C. scindens, another Clostridium species, was correlated with strong C. 
difficile inhibition in both humans and mice199. As proof of concept, colonization by a 
human C. scindens isolate diminished C. difficile infection and disease severity in mice. 
The investigators showed that C. scindens was able to convert primary bile acids into 
secondary bile acids, deoxycholate and lithocholate, which are inhibitory to C. difficile 
vegetative cell growth, leading to infection resistance199. A simplified summary of 
several proposed beneficial bacteria under study is presented in Table 1. Furthermore, 
recent research indicates that destruction, specifically of the indigenous obligate 
anaerobes of the gut, contributes to the expansion of pathogenic bacteria, demonstrating 
their vital role in colonization resistance200,201. It is likely that researchers will begin to 
focus their efforts more specifically on these strict anaerobes. 
Although technical challenges exist in studying interactions between bacteria 
requiring strict anaerobic conditions and human colonocytes requiring aerobic conditions, 
recent advancements in the development of dual-environment co-culture models will 
allow for better study of these mechanisms. For instance, the ‘apical anaerobic co-culture 
model’, developed by Ulluwishewa et al., allows for the study of anaerobic bacteria in 
direct contact with human cell lines for up to 12 hours202. Used in an anaerobic 
workstation, this device has an upper chamber containing anaerobic medium for obligate 
anaerobes and a lower chamber containing aerobic medium, separated by a microporous 
membrane. Human cell lines are seeded on top of the membrane with the diffusion of 
oxygen occurring from the aerobic medium underneath. Due to built-in electrodes, trans-
epithelial resistance can be measured to assess intestinal barrier function and distinct 
compartment separation allows for sampling of the basal medium without system 
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disruption. For instance, paracellular tracers could be administered on the luminal side 
and tight junction integrity evaluated by collection on the basal side. To simulate a more 
physiological gastrointestinal tract, mucus-secreting cell lines, such as HT29-MTX, could 
be seeded to induce mucus layer separation of microbes from intestinal epithelial cells 
(IECs). One can even envision the study of more complex interactions of microbes and 
IECs along with immune cells of various types, currently under development. The further 
incorporation of intestinal enteroids, three-dimensional ‘mini-intestines’203, in 
combination with co-culture systems would provide an even more powerful tool to study 
these interactions.  
 I propose the rigorous study of probiotic organisms using a two-pronged 
approach, utilizing both germ free animals and dual-environment co-culture modeling to 
elucidate individual bacteria and community effects. For both experimental arms, first, 
individual bacterial species would be studied in isolation in monocolonized GF mice to 
establish effects on the host in vivo and in co-culture systems to establish initial host-
microbe interactions in vitro. Second, after establishing the mechanistic effects of single 
species on the host or on cultured human cells, varied combinations of bacterial species 
would be introduced in both systems. These experiments would help determine whether 
specific bacteria have the capability to co-colonize in the host, and if so, to analyze any 
synergistic impact. For instance, is there combined host cell benefit of specific microbes 
together and to what extent? Can we customize the ideal composition of ‘good’ 
microbes? Beyond these experiments, meticulous study should take place in the clinic to 
examine the proportions of specific ‘good microbes’ in healthy individuals. We need to 
know whether ‘adequate’, durable colonization can be achieved in humans through 
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different approaches, such as oral treatment, microbial transplantation, and dietary 
changes.  
 
The Bright Future of Microbial-Based Therapies  
 Excitingly, the next generation of microbial therapy is already moving towards 
potential applications in cancer treatment. In recent years, checkpoint blockade 
immunotherapy, aimed at impeding inhibitory immune cell checkpoints, has begun to 
revolutionize patient standard of care with, for example, demonstrated efficacy in cases 
of malignant melanoma204, renal cell cancer205, and non-small-cell lung cancer206. The 
current checkpoint blockades approved by the Food and Drug Administration target 
suppressive receptors on the surface of T cells, e.g. cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4) and programmed cell death 1 (PD-1), with the goal of unleashing the 
endogenous antitumor immune response. Nevertheless, it should be underscored that only 
a subset of patients responds favorably to such treatments with various aspects of the 
tumor microenvironment, the tumor itself, and circulating factors as contributors to 
response outcome. New research has now implicated the gut microbiome as another 
important modulating factor.   
 In a mouse melanoma model, Sivan et al. showed that mice housed in two 
different facilities (Jackson Laboratory (JAX) and Taconic Farms (TAC)) and known to 
have differential microbial makeups, exhibit different rates of tumor growth (slower in 
JAX mice); this difference disappeared after co-housing, with all co-housed mice 
seeming to display the JAX, slower-growing tumor phenotype207. The transfer of feces 
from JAX mice to TAC mice also resulted in slower-growing tumors and greater tumor 
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infiltration with CD8+ T cells in TAC mice. Interestingly, anti-PD-L1 antibody treatment 
was more effective in JAX mice than in TAC mice and more effective in TAC mouse 
recipients of JAX stool than either fecal transfer or anti-PD-L1 treatment alone. Further 
16S rRNA analysis of mice that received JAX feces revealed an increased abundance in 
bacteria of the genus Bifidobacterium that associated with antitumor T cell responses. 
Furthermore, colonization by live Bifidobacterium spp. mimicked the results of the JAX 
stool transfer, implicating Bifidobacterium in antitumor immunity and improved anti-PD-
L1 treatment efficacy.  
In the same melanoma mouse model, Vétizou et al. showed that mice housed in 
specific pathogen free (SPF) conditions responded to anti-CTLA-4 treatment exhibiting 
diminished tumor growth, whereas mice housed in germ free (GF) conditions did not208. 
Additionally, the treatment of SPF mice with broad-spectrum antibiotics diminished anti-
CTLA-4 therapeutic efficacy. Anti-CTLA-4 treatment altered the microbiome, resulting 
in the enrichment of Bacteroides spp. (specifically B. thetaiotaomicron and B. uniformis) 
in the small intestine, contrasting with a fecal decrease of these bacteria. When antibiotic-
treated SPF mice or GF mice were inoculated with different Bacteroides isolates, the 
checkpoint therapy regained effectiveness. Similarly, ipilimumab (anti-CTLA-4) 
treatment in metastatic melanoma patients initiated a fecal clustering of microbes more 
abundant in distinct Bacteroides spp.. The fecal microbial transfer (FMT) of these patient 
stools to GF mice resulted in improved anti-CTLA-4 efficacy and increased colonization 
levels of B. fragilis and B. thetaiotaomicron, demonstrating the compelling potential for 
human gut microbes as a tool to boost cancer immunotherapy responses. While many 
questions remain, these studies provide strong evidence that intestinal microbes can affect 
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responses to checkpoint blockade therapy and that intestinal microbes can be manipulated 
for a beneficial therapeutic outcome.  
Study in and application of microbiome science to human clinical disease is not 
without significant challenges. Human patients live in distinct geographic locations and 
environments, exhibiting a vast array of dietary habits, social customs, and physical 
activity. In contrast to the convenience and simplicity of laboratory mice used in 
modeling studies, the complex variability in the human environment, behaviors, and 
exposures, likely contribute to vast inter-patient differences regarding the makeup of their 
gut microbiomes. For instance, preliminary data gathered by the Sears group has begun to 
identify key differences in the prevalence of colon tumor-associated and normal tissue-
flanking invasive biofilms in CRC patients sampled from two distinct populations, 
Malaysia and the United States. The U.S. cohort exhibits an almost universal detection of 
invasive biofilms in the right (89%), defined as ascending colon to the hepatic flexure, 
versus the left colon (12%)135. And while invasive biofilms are primarily detected in the 
right colon, the gap between right and left colon detection appears to significantly narrow 
in the Malaysian cohort. In addition, the habitual exposure of cancer patients requiring 
chemotherapy to antibiotics and antibiotic-resistant bacteria also contributes to alterations 
in the development of their microbiomes201. Multifaceted research approaches will be 
needed to address these distinct variables.      
Although complex, this endeavor is a worthwhile pursuit. Microbial manipulation 
holds promise, not just for the treatment of cancer, but also for other diseases such as 
microbial infection, inflammatory bowel disease, obesity, and arthritis. For example, 
colon microbial alteration by fecal microbiota transplantation (FMT) has shown 
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remarkable effectiveness in treating recurrent Clostridium difficile infection (CDI) in 
patients, with relapse-free cure rates of 80-90%209. And although not yet studied in 
randomized controlled trials (RCTs), there are early case reports of FMT or FMT-like 
therapies leading to clearance of other pathogenic or drug-resistant bacteria. A secondary 
analysis of patients in a CDI phase 2 trial with RBX2660, a microbiota-based drug 
derived from live human microbes, also showed evidence of effectiveness against 
vancomycin-resistant Enterococcus (VRE) colonization210. Bilinski and colleagues found 
that FMT treatment of an immunocompromised patient led to clearance of β–lactamase-
positive Klebsiella pneumoniae and ESBL-positive E. coli colonization211. In addition, 
Crum-Cianflone and colleagues found that a single patient treated by FMT for recurrent 
CDI also had the added benefit of clearing carbapenem-resistant Enterobacteriaceae, 
MRSA, VRE, and multi-drug resistant Acinetobacter baumannii, lessening the burden of 
infection, sepsis, and antibiotic usage post-FMT212.  
As described in Chapter 1, IBD is associated with intestinal dysbiosis with noted 
decreased bacterial phyla diversity, namely in Firmicutes and Bacteroidetes. In 
functionality, the microbiome of IBD patients may also diverge, with changes observed 
in oxidative stress pathways and carbohydrate metabolism213. Still in the early stages of 
study, so far, the results of FMT efficacy in the treatment of IBD have been 
heterogeneous. In two RCTs of active ulcerative colitis, one yielded no significant 
difference in clinical remission but increased bacterial diversity in responsive subjects 
(n=50)214, and another showed a greater proportion of FMT recipients versus placebo 
(24% vs 5%) in remission 7 weeks post-FMT (n=75)215. Interestingly, the FMT-recipients 
from a specific donor (donor B) appeared more responsive, suggestive of a donor-effect 
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in the context of IBD, a finding not observed in the recurrent C. difficile infection FMT 
literature215. The results of study in Crohn’s disease patients have been similarly mixed. 
Thus, FMT therapy in IBD patients warrants further study. Although prospective data is 
lacking on pre- or probiotic treatments in obesity, a recent study evaluated three probiotic 
strains, Lactobacillus paracasei, Lactobacillus rhamnosus, and Bifidobacterium animalis 
in mice fed a high fat diet for 12 weeks. Treatment by individual strains led to diminished 
weight gain and improved glucose-insulin homeostasis, while also shifting the gut 
microbiota to that of lean diet fed mice216. Furthermore, FMT treatment of germ free 
mice with stool from conventionally-raised mice with a genetic predisposition to obesity 
led to the development of phenotypically obese mice217–219. Similarly, a recent case report 
described a patient who developed new-onset obesity after a successful FMT procedure 
receiving feces from an overweight donor220. Collectively, these studies provide insight 
into the transmissibility of the ‘obese’ microbiota and suggest that microbial intervention 
may help combat this condition.  
Arthritis, another immune-mediated disease, has also been associated with oral 
and intestinal dysbiosis; increased Prevotella, Leptotrichia, and Lactobacillus species 
have been observed in rheumatoid arthritis and overall decreased bacterial diversity has 
been observed in psoriatic arthritis221. And while probiotic treatment in arthritis patients 
has typically yielded negative results, dietary intervention with a vegan or Mediterranean-
style diet has led to moderate improvements221. Clinical trials analyzing FMT therapies in 
rheumatic diseases have not been carried out but will likely soon be initiated.   
In an age where antibiotic resistance is rapidly increasing while the discovery or 
synthesis of new antibiotics is waning, and diseases of the bowel and of an autoimmune 
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nature are significantly increasing, it is essential that the study and honing of microbiota-
based methods progress. Unleashing the power of naturally occurring, symbiotic 
microbes may be a way to partly address these continuing challenges. At a basic level, 
the continued study of microbes in isolation, utilizing gnotobiotic mice, and the 
development of better methods to study complex communities of microbes together and 
with their host are key to moving this ambitious goal forward. At a translational level, the 
prospective analysis of the intestinal microbiota prior and in response to clinical 
treatments including cancer immunotherapy, antibiotics, and FMT, is essential to 
developing safe and effective future therapies. The future is fecal! 
 
A Translational Approach to Studying IL-22  
 While animal models have yielded the functional dualities of IL-22, in that this 
cytokine appears to have the capacity for both preventative and permissive effects in both 
the development of chronic colitis and colon cancer development, much remains to be 
learned in its role in clinical disease. From seminal work carried out by Dejea et al., we 
learned that invasive polymicrobial biofilms were a key feature of right-sided colon 
tumors and matched normal tissues within the patient135. The presence of biofilms was 
also associated with diminished E-cadherin and enhanced IL-6 and STAT-3 activation in 
colon epithelial cells. It is likely that other cell-intrinsic or cell-extrinsic factors are 
influenced by the presence of these biofilms, and it will be exciting to uncover its 
possible effect on the IL-23/IL-22 axis. Furthermore, understanding how tumor 
mutational status and/or microsatellite status contributes to this complex web of 
interaction is of great interest. In collaboration with Fiona Powrie’s laboratory at Oxford 
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University, who has begun to uncover some intriguing associations of tumor mutational 
status and IL-22 receptor expression profiles relating to CRC prognosis, we will begin to 
address some of these questions. Existing CRC clinical samples made available through 
the Johns Hopkins Hospital and UMMC in Kuala Lumpur, Malaysia have already been 
analyzed for invasive biofilm status. From a select pool, preliminary IL-22 and IL-22R 
expression will be analyzed by immunohistochemical means and confirmed with 
quantitative PCR where frozen tissues are available; in consort, genotyping of samples 
will be done to determine tumor mutational status. Understanding the impact of IL-22 
signaling in CRC may yield important insights into CRC prognosis and treatment 
















Table 1: Proposed beneficial bacteria under study  
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